1,'$&713URWRFRO
([WHQGHG5HOHDVH1DOWUH[RQHYV
%XSUHQRUSKLQHIRU2SLRLG7UHDWPHQW
;%27
/HDG,QYHVWLJDWRU/, -RKQ5RWURVHQ0'
&R/, -RVKXD/HH0'06F
(GZDUG1XQHV0'
3URMHFW0DQDJHU 3D WULFLD1RYR03+
3URWRFRO'DWH$XJXVW
9HUVLRQ

NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] ( X:BOT)  August 31, 2015  
 
PROTOCOL DEVELOPMENT TEAM  
 
Genie L. Bailey, MD  
Gregory S. Brigham, PhD  
Arthur L. Caplan, PhD  
Allan J. Cohen, MA, MFT 
Marc Fishman, MD  
Michael T. French, PhD  
Mary Jeanne Kreek, MD  
Walter Ling, MD  
Dennis McCarty, PhD  
Larissa J. Mooney, MD  
Susan A. Murphy, PhD  
Dominic Sisti, PhD  
George Woody, MD  
 
EMMES:  
Robert Lindblad, MD  
Ro Shauna Rothwell, PhD 
Dee Blumberg, PhD  
Don Stablein,  PhD 
Paul Van Veldhuisen,  PhD 
Colleen Allen, MPH  
Jeanine May,  PhD 
Dagmar Salazar , MS 
 
CCTN: 
Petra Jacobs, MD  
David Liu, MD  
Steven Sparenborg, PhD  
Geetha Subramaniam, MD  
Betty Tai, PhD  
Paul G. Wakim, PhD  
   
 
 
 
  
 
 
 
  
 
 
 
  
2 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] ( X:BOT)  August 31, [ADDRESS_9127] OF ABBREVIATIONS  ............................................................................................  7 
2.0 CTN-0051 SYNOPSIS AND SCHEMA  ............................................................................ 9  
3.0 CTN-0051 TIMELINE  .................................................................................................... 11 
4.0 INTRODUCTION ........................................................................................................... 12 
4.1 Background and Rationale......................................................................................... 12 
4.2 Naltrexone (NTX) and Extended- Release Naltrexone (XR- NTX)  ............................... 13 
4.3 Buprenorphine (BUP) and Buprenorphine/Naloxone Combination (BUP -NX) ............ 14 
4.4 Significance to the Field  ............................................................................................. 15 
5.0 CTN-0051 OBJECTIVES  ..............................................................................................  17 
5.1 Primary Objective  ...................................................................................................... 17 
5.2 Secondary Objectives  ................................................................................................ 17 
6.0 STUDY DESIGN  ........................................................................................................... 18 
6.1 Overview  of Protocol Study Design ............................................................................ 18 
6.2 Treatment Initiation .................................................................................................... 19 
6.3 Duration of Study and Visit Schedule  ......................................................................... 19 
7.0 STUDY POPULATION  .................................................................................................. 20 
7.1 Inclusion Criteria  ........................................................................................................ 20 
7.2 Exclusion Criteria  ....................................................................................................... 20 
7.2.1  Special Populations to Consider  ........................................................................ 21 
7.3 CTP Sites  .................................................................................................................. 21 
8.0 STUDY PROCEDURES  ................................................................................................ 22 
8.1 Recr uitment and Screening (Phase 1)  ....................................................................... 22 
8.1.1  Informed Consent (Phase 1)  .............................................................................. 22 
8.1.2  Detoxification  ..................................................................................................... 22 
8.1.3  Screening and Baseline Assessments (Phase 1)  ............................................... 22 
8.2 Randomization (Phase 1, Day 0)  ............................................................................... 23 
8.3 Stratified Randomization ............................................................................................  23 
8.4 Induc
tion (Phase 2)  ................................................................................................... 23 
8.5 Study Treatments (Phase 3)  ...................................................................................... 24 
8.5.1  XR-NTX Group  .................................................................................................. 25 
8.5.2  BUP-NX Group  .................................................................................................. 25 
8.5.3  Dispensing of XR -NTX and BUP -NX .................................................................. 26 
8.6 Drug Packaging/Handling/Storage/Accountability  ...................................................... 27 
8.6.1  Study Medication Management  .......................................................................... 27 
8.6.2  Drug  Accountability Records and Dispensing of Study Medication ..................... 27 
8.6.3  Study Medication Storage .................................................................................. 27 
3 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] ( X:BOT)  August 31, 2015  
 
8.6.4  Used/Unused Medication ................................................................................... [ADDRESS_9128] Medication .................................................................................................. 27 
8.6.6  Dispensing of Study Medications  ....................................................................... 27 
8.6.7  Drug Packaging ................................................................................................. 28 
8.7 Blinding ...................................................................................................................... 28 
8.8 Participant compensation .......................................................................................... 28 
9.0 OUTCOME MEASURES  ............................................................................................... 29 
9.1 Primary Outcome ....................................................................................................... 29 
9.2 Secondary Outcomes  ................................................................................................ 29 
10.0  PARTICIPANT DISCONTINUATION, FOLLOW -UP ..................................................... 31 
10.1  Treatment Discontinuation ......................................................................................... 31 
10.2  Follow -Up (Phase 4)  .................................................................................................. 31 
11.0  STUDY FORMS, PROCEDURES AND ASSESSMENTS  ............................................. 32 
11.1  General ...................................................................................................................... 34 
11.1.1  Inclusion/Exclusion  ............................................................................................  34 
11.1.2  Locator Form  ..................................................................................................... 34 
11.1.3  Demographics Form  .......................................................................................... 34 
11.1.4  PhenX Tier 1  ...................................................................................................... 34 
11.1.5  Motivations, Attitudes, and Expectations Form  ................................................... 34 
11.1.6  Treatment Satisfaction Survey  ........................................................................... 34 
11.1.7  Relapse ............................................................................................................. 35 
11.1.8  Continuing Treatment Forms  ............................................................................. 35 
11.1.9  Study Termination Form  ..................................................................................... 35 
11.2  Safety and Medical  .................................................................................................... 35 
11.2.1  Medical and Psychiatric History  ......................................................................... 35 
11.2.2  Physical Examination ......................................................................................... 35 
11.2.3  DSM -5 Criteria  ................................................................................................... 35 
11.2.4  Concise Health Risk Tracking -Self Report (CHRT -SR) ...................................... 35 
11.2. 5 C
linical Laboratory Tests .................................................................................... 36 
11.2.6  Pregnancy and Birth Control Assessment  .......................................................... 36 
11.2.7  Adverse Events (AEs) and Serious Adverse Events (SAEs)  .............................. 36 
11.2.8  Injection Site Examination .................................................................................. 37 
11.3  Compliance ............................................................................................................... 37 
11.3.1  Dose Logs .......................................................................................................... 37 
11.3.2  Medical Management  ......................................................................................... 37 
11.3.3  Psychosocial Participation ................................................................................. 37 
11.4  Drug Use and Psychological  ...................................................................................... 38 
11.4.1  Timeline Follow -Back (TLFB)  ............................................................................. 38 
11.4.2  Urine Drug Screen (UDS)  .................................................................................. 38 
11.4.3  Addiction Severity Index Lite (ASI -Lite) .............................................................. 38 
4 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] ( X:BOT)  August 31, 2015  
 
11.4.4  Visual Analog Scales (VAS)  ............................................................................... 38 
11.4.5  The Hamilton Depression Scale (17 item) (HAM -D) ........................................... 38 
11.4.6  The Subjective Opi[INVESTIGATOR_9721] (SOWS)  .............................................. [ADDRESS_9129] for Nicotine Dependence (FTND)  ............................................ 39 
11.4.8  Risk Assessment Battery (RAB)  ......................................................................... 39 
11.4.9  Cognitive Function Tests  .................................................................................... 39 
11.4.10  Detoxification Utilization Form  ............................................................................ 39 
11.4.11  EuroQol (EQ -5D) ............................................................................................... 39 
11.4.12  Non-Study Medical and Other Services (NMS)  .................................................. 39 
11.5  Genetics Protocol Measures  ...................................................................................... 40 
12.0  STATISTICAL ANALYSIS  ............................................................................................  41 
12.1  General Design  .......................................................................................................... 41 
12.1.1  Primary and Secondary Outcomes (Endpoints) ................................................. [ADDRESS_9130] Approvals  ......................................................................... 48 
13.3  Research Advisory Panel of [LOCATION_004] ([LOCATION_004] sites only)  ..................................... [ADDRESS_9131] (HIPAA) ..................................... 49 
13.4.2  Investigator Assurances  ..................................................................................... 49 
13.4.3  Financial Disclosure ........................................................................................... 49 
13.5  Drug Accountability  .................................................................................................... 49 
13.5.1  DEA Registration  ............................................................................................... 49 
13.5.2  Inclusion of Women and Minorities  .................................................................... 49 
13.5.3  IND Requirements  ............................................................................................. 50 
13.5.4  Regulatory Files  ................................................................................................. 50 
13.5.5  Records Retention and Requirements  ............................................................... 50 
13.5.6  Audits  ................................................................................................................. 50 
5 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] ( X:BOT)  August 31, [ADDRESS_9132] (DSMB)  ........................................................ 52 
13.6.3  Protocol Deviations Reporting and Management ............................................... 52 
13.6.4  Adverse Events (AEs)  ........................................................................................ 53 
13.6.5  Serious Adverse Events  ..................................................................................... 54 
13.6.6  Known Potential Toxicities of Study Drug/Intervention ....................................... 54 
14.0  DATA MANAGEMENT AND PROCEDURES  ............................................................... 55 
14.1  Design and Development  .......................................................................................... 55 
14.2  Site Responsibilities ................................................................................................... 55 
14.3  Data Center Responsibilities  ...................................................................................... 55 
14.4  Data Collection  .......................................................................................................... 55 
14.5  Data Acquisition and Entry ......................................................................................... 55 
14.6  Data Editing  ............................................................................................................... 55 
14.7  Data Lock and Transfer  ............................................................................................. 56 
14.8  Data Training ............................................................................................................. 56 
14.9  Data QA ..................................................................................................................... 56 
15.0  PUBLICATIONS AND OTHER RIGHTS  ....................................................................... 57 
16.0  SIGNATURES  ............................................................................................................... 58 
17.0  REFEREN CES .............................................................................................................. 59 
18.0  APPENDICES  ............................................................................................................... 64 
APPENDIX A ‚Äì Adverse Event Reporting Definitions and Procedures  .............................. 65 
APPENDIX B ‚Äì Data Safety and Monitoring Plan  .............................................................. 70 
APPENDIX C ‚Äì XR-NTX ................................................................................................... 74 
APPENDIX D ‚Äì BUP-NX ................................................................... .............................. 106 
  
6 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9133] Aspartate Aminotransferase 
BMI Body Mass Index  
BP Blood Pressure  
BUP Buprenorphine  
BUP-NX  Buprenorphine+Naloxone (Suboxone¬Æ)  
CAP  College of American Pathologists  
CCC  Clinical Coordinating Center  
CFR Code of Federal Regulations  
CHRT  Concise Health Risk Tracking  
CLIA  Clinical Laboratory Improvement Amendment of [ADDRESS_9134] 
IM Intramuscular  
IV Intravenous  
LFTs  Liver Function Tests (AST, ALT , albumin and bilirubin) 
LI Lead Investigator  
MD Medical Doctor  
MDMA  Methylenedioxymethamphetamine (Ecstasy)  
MedDRA  The Medical Dictionary for Regulatory Activities  
Mg  Milligrams  
7 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
MM Medical Management  
MOP  Manual of Operations  
NDA  New Drug Application 
NIAAA National Institute on Alcohol Abuse and Alcoholism  
NIDA  National Institute on Drug Abuse  
NIH National Institutes of Health 
NMS  Non-Study Medical and Other Services  
NP Nurse Practitioner  
NTX  Naltrexone 
NX Naloxone  
OHRP  Office for Human Research Protections  
PA Physician Assistant  
PI  [INVESTIGATOR_9722] -co-glycolide  
QA Quality Assurance  
RAB  Risk Assessment Battery  
RAP-C Research Advisory Panel of [LOCATION_004]  
RRTC Regional Research and Training Center  
SAE Serious Adverse Event  
SC Subcutaneous  
SOWS  Subjective Opi[INVESTIGATOR_9723] -Back 
UDS  Urine Drug Screen  
VA Veterans Administration  
VAS  Visual Analog Scale  
XR-NTX Extended- Release Naltrexone (Vivitrol¬Æ) 
8 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9135] will relapse to opi[INVESTIGATOR_9724], leading to a costly and ineffectual cycle of 
readmission for repeated detoxifications.   
The overarching goal of CTN -0051 is to foster adoption of new relapse- prevention 
pharmacotherapi[INVESTIGATOR_9725] -based treatment programs (CTPs) where these could have a 
substantial public health impact.  To this end CTN -0051 will assess the comparative 
effectiveness of extended release injectable naltrexone (XR -NTX, Vivitrol¬Æ), an opi[INVESTIGATOR_9726], 
versus buprenorphine- naloxone (BUP- NX, Suboxone¬Æ), a high affinity partial agonist indicated 
for maintenance treatment of opi[INVESTIGATOR_2561] , as pharmacotherapeutic aids to recovery.   
The study is conducted in 8 CTN- affiliated CTPs that provide or partner with detoxification 
services (inpatient/residential)  which  have the capacity to maintain participants opi[INVESTIGATOR_2480]- free for 
approximately 3- [ADDRESS_9136] the capacity  to provide medication- assisted therapy, and can 
provide a minimum of one group or individual counseling session per week during the 24- week 
treatment period.  Up to 600 eligible participants will be randomized to treatment with XR -NTX 
or BUP -NX for 24 weeks (sufficient to include [ADDRESS_9137] opi[INVESTIGATOR_2480]). To maximize generalizability, the point of randomization is 
flexible, from shortly after program admission until just prior to program discharge. A data 
analysis  modification (assessment of whether the early vs . late randomizers have a differential 
treatment effect and if so, time to relapse will be estimated for early and late randomizers 
separately ) will occur if differential treatment initiation is a problem for cases randomized prior to 
completing detoxification (i.e., significantly fewer early randomizers are able to complete 
detoxification and XR- NTX induction) . 
The primary goal of the study is to estimate the difference, if one exists, between XR-NTX and 
BUP-NX in the distribution of the time to relapse (i.e. , loss of persistent abstinence) during the 
6-month trial.  The primary outcome measure is the time to the event, with the event called 
relapse.  Secondary objectives are to: (1) compare outcome on XR -NTX versus BUP -NX across 
a range of clinical safety and secondary efficacy domains, (2) explore demographic , clinical, and 
genetic  predictors of successful treatment and moderators of differential effectiveness (i.e., what 
variables may help clinicians choose which of these treatments is best for a given patient), and 
(3) collect a limited dataset to permit analyses of economic costs and benefits of the two treatments . 
Toward the end of the 24- week treatment period, participants are referred for follow -up care in 
the community  (which could include pharmacotherapy if desired and available) , and follow -up 
outcomes are assessed at week 28 and week 36 after randomization.  For participants receiving 
BUP-NX, who do not wish to continue, or for whom community resources are not available, the 
study provides a two -week BUP -NX taper . 
  
9 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
Figure 1: CTN -0051 Schema  
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
  
*The window for induction remains open into Phase 3 (until week 22).  
Phase 1  
Phase 2 * 
 
Phase 3  
 
Phase 4  
 
Candidate enters treatment program  
Study is explained, candidate consents  
(can occur at any time- point between 
program admission and discharge)  
Participant is randomized  
XR-NTX 
 BUP-NX 
 
Achieve sufficient withdrawal  
   (or have already completed  
   detoxification) to induct onto  
   BUP- NX 
Initiate BUP -NX  
Complete detoxification  
Achieve 3+ days abstinence  
Negative UDS  
Negative NX challenge  
First XR -NTX injection  
Treat for 24 weeks  
Weekly visits  
Refer to community -based treatment  
Follow up at week 28 and week 36 
Participant meets eligibility criteria  
Treatment Failures, 
Dropouts  
10 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9138] up to 38 months  at participating sites .  A phased startup, 
with two or three sites starting several months before the others, is anticipated.  The timeline is 
as follows:  
‚Ä¢ Study start up (IRB approvals, hiring, training): up to 3 months  
‚Ä¢ Enrollment: up to 24 months  
‚Ä¢ Treatment: 6 months  
‚Ä¢ Follow -up: 3 months  
‚Ä¢ Data lock: 2 months  
11 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9139] substitution, i nitially with 
methadone and more recently with buprenorphine, is both efficacious in clinical trials and 
effective in the community in promoting and sustaining abstinence and reducing risks associated with opi[INVESTIGATOR_2561].
1,2 Despi[INVESTIGATOR_6831], ‚Äúdrug -free‚Äù non- medication- based 
strategies, such as short -term detoxification followed by [CONTACT_9848], while 
associated with high relapse rates, remain a mainstay of treatment in U.S. community -based 
settings.3,[ADDRESS_9140] 
agonists, individual preference to be ‚Äúdrug -free‚Äù, and limited access to medication and 
providers.  Naltrexone (NTX), a full mu- opi[INVESTIGATOR_9727], has been FDA -approved for opi[INVESTIGATOR_9728] 1980s, but in its orally administered form it is largely ineffective, it has virtually no place as first- line opi[INVESTIGATOR_2512], and it is little used in the community.
5-6  Two 
recent studies of XR-NTX ( Comer et al.7, testing Depotrex¬Æ, Biotech Inc., in [LOCATION_001] City and 
Philadelphia; and Krupi[INVESTIGATOR_9729].8, testing Vivitrol¬Æ, Alkermes Inc., in Russia) support efficacy of 
XR-NTX compared to placebo injections.  
In October 2010, largely on the basis of the Russian trial and an earlier U.S. safety study (Alkermes ALK21 -006 and ALK21- 006-EXT), the FDA approved Vivitrol
¬Æ for the ‚Äúprevention of 
relapse to opi[INVESTIGATOR_2561]‚Äù.  Patients and treatment program s now have a remarkable 
opportunity to choose between two pharmacologically distinct and opposite treatment 
approaches, XR -NTX and BUP -NX, each with established efficacy.  Yet, little is known about 
XR-NTX implementation in U.S. community -based settings, and the FDA‚Äôs decision has been 
criticized insofar as (1) the FDA ‚Äúaccepted a single trial of injectable naltrexone in Russia, unpublished at the time, as primary evidence of efficacy‚Äù, and (2) ‚Äúthe study did not adequately 
assess risk of post -treatment over dose‚Äù.
9, [ADDRESS_9141] therapy is prohibited in Russia, these 
authors question the use of these ‚Äúdata to gain approval in the [LOCATION_003] ‚Äì where methadone and 
buprenorphine are widely available‚Äù.  
Regardless of the merit of these concerns, the data from the Russian placebo- controlled 
efficacy trial do not directly ad dress the effectiveness, comparative effectiveness, safety, and 
costs of XR -NTX in U.S. community -based populations and treatment programs.  There are few, 
if any, data to guide choice and to direct patient -centered treatment decisions.  It is i n this 
context that our primary goals are to learn and inform the field about XR -NTX implementation in 
the community and to compare that to BUP -NX ‚Äì specifically with regard to population and 
treatment program characteristics associated with successful out comes ‚Äì to foster more 
widespread adoption of new pharmacotherapi[INVESTIGATOR_9730].  Our aims are to clearly 
address key questions emerging from the availability of mechanistically opposite treatment 
options and to develop pi[INVESTIGATOR_9731].  Overall, are the two approaches (XR -
NTX vs. BUP -NX) essentially equally effective?  Are there demographic, and/or clinical factors 
associated with favorable treatment outcome overall, or that predict better outcome with one approach vs. the other ? What treatment -program characteristics are associated with success 
with each of the treatments?   
A key design consideration to highlight early in this introduction is that induction from active 
opi[INVESTIGATOR_9732] -NTX and BUP -NX differs substantially.  Ideally (though not necessarily 
typi[INVESTIGATOR_897]) BUP -NX induction is initiated in the very early phase of opi[INVESTIGATOR_9733] -NX 
maintenance is pursued instead of opi[INVESTIGATOR_9734].  In contrast, because naltrexone is a full 
12 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9142] -detoxification aftercare, 
particularly as patients entering a treatment facility are often in crisis, not yet aware of the full menu of treatment options, and often don‚Äôt recognize or accept that they are unlikely to succeed in aftercare without medication.  Further, for many patients, information about access to ‚Äì and 
third-party payment for ‚Äì BUP-NX maintenance is often not available until late in the course of a 
detoxification admission, if it is available at all.  For these reasons, it is not uncommon to initiate 
BUP-NX treatment during or following detoxification, and there are CTN CTPs that have 
standard operating procedures for this.  Further, in discussions with clinical sites for this trial, it 
has become clear that in many parts of the U.S., medication treatment is not available for most 
opi[INVESTIGATOR_2480]- dependent patients, due to a combination of lack of services or practitioners and lack of 
third-party coverage.  Hence, there is a large population of opi[INVESTIGATOR_2480]- dependent patients who enter 
detoxification programs to which the findings of the proposed trial should generalize.  To 
maximize generalizability, the point of randomization is flexible, from shortly after program 
admission until just prior to program discharge. A data analysis  modification ( assessment of 
whether the early vs . late randomizers have a differential treatment effect and if so, time to 
relapse will be estimated for early and late randomizers separately )  will occur if differential 
treatment initiation is a problem for cases randomized prior to completing detoxification (i.e., 
significantly fewer early randomizers are able to complete detoxification and X R-NTX induction) . 
4.2 Naltrexone (NTX) and Extended- Release Naltrexone (XR -NTX) 
NTX is a potent opi[INVESTIGATOR_9735]- opi[INVESTIGATOR_9736].  In the U.S. it is 
approved for use in treating opi[INVESTIGATOR_9737].  It is hi ghly efficacious 
in preventing relapse to opi[INVESTIGATOR_9738], but 
adherence with oral naltrexone is problematic and leads to extremely high dropout rates, with the occasional exception of treatment in criminal justice and other settings where relapse may 
be linked to severe adverse consequences.
11-13  This has led to intensive efforts ‚Äì including 
NIDA - and NIAAA -funded grants to small businesses ‚Äì to develop long- acting naltrexone 
preparations that can be administered as an injection or placed as an implant once per month or 
less frequently.14,15 
XR-NTX (Vivitrol¬Æ, NTX -containing polylactide-co- glycolide [PLG] biodegradable sterile 
microspheres suspended in a diluent) is delivered by [CONTACT_9849].  Each vial of microspheres contains [ADDRESS_9143] and shaking for about a minute prior 
to injection of the ‚Äúfull‚Äù (less dead- space) content of the vial.  Plasma concentrations of NTX and 
6-beta naltrexol (its main active metabolite) after a single XR -NTX injection are detectable for at 
least 30 days.  Consistent with this, in human laboratory studies with Vivitrol
¬Æ and Depotrex¬Æ, 
essentially complete blockade of opi[INVESTIGATOR_9739] [ADDRESS_9144] be re- administered.  Long- term use of NTX and XR -
NTX is not associated with tolerance, dependence, addiction or withdrawal on discontinuation.  
NTX and XR -NTX will, however, p recipi[INVESTIGATOR_9740].  
13 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
As a consequence of its extended duration of action and ‚Äúassured‚Äù treatment adherence, XR -
NTX may dramatically  and favorably alter the limited effectiveness profile associated with orally 
administered NTX.  By [CONTACT_9850] 30 -day medication adherence with a single injection, and 
thereby [CONTACT_9851] a ~[ADDRESS_9145] blockade, the likelihood of an individual re-
establishing opi[INVESTIGATOR_9741].  The two clinical trials cited above 
(Comer et al.7, and Krupi[INVESTIGATOR_9729].8) support efficacy for XR -NTX preparations compared to 
placebo injections.  
The [ADDRESS_9146] (Depotrex¬Æ, Biotek Inc.), and showed that long -
acting injectable naltrexone in conjunction with outpatient counseling produced superior 
treatment re tention to placebo, providing ‚Äúevidence of the feasibility, efficacy, and tolerability of 
long-lasting antagonist treatments for opi[INVESTIGATOR_2561]‚Äù.  
The Krupi[INVESTIGATOR_9729]. study8 was conducted in 2008 and 2009 in 13 sites in Russia, and was 
sponsored by [CONTACT_3455], Alkermes Inc.  Following inpatient detoxification, 250 opi[INVESTIGATOR_2480]-
dependent patients were randomized to XR -NTX (Vivitrol¬Æ) or placebo, double- blind monthly 
injections, for 6- months, during which all patients received outpatient counseling.  The percent 
of opi[INVESTIGATOR_9742], by [CONTACT_9852], was the primary outcome.  A response profile analysis compared the cumulative percent of patients at each level of the outcome 
(percent opi[INVESTIGATOR_2480]- free weeks) between the activ e XR -NTX and placebo conditions.  The difference 
between the response profiles was significant (p < .0002), with the median patient on XR -NTX 
having 90% abstinent weeks compared to 35% abstinent weeks for the median patient on 
placebo.  Total abstinence (100% opi[INVESTIGATOR_2480]-free weeks) was reported in 45 (35.7%) subjects in the 
XR-NTX group versus 28 (22.6%) subjects in placebo group (p < .03).  Retention in treatment 
for the full 6 months was 53% on XR -NTX, compared to 38% on placebo (p < .02).  The 6 -
month retent ion rate in the 50% range is similar to that observed in clinical trials of 
buprenorphine.
2  Patients treated with XR -NTX showed an approximately 50% sustained 
reduction in craving compared to no change in craving in the placebo group (p < .005).  XR -NTX 
was generally well tolerated.  Data from this pi[INVESTIGATOR_9743] ‚Äô supplemental NDA 
for treatment of opi[INVESTIGATOR_2561]. 
Prescribing and Safety:  Details on XR -NTX ( Vivitrol¬Æ) prescribing, pharmacokinetics and 
pharmacodynamics, metabolism and elimination, safety and toxicity are in Appendix C.  
4.3 Buprenorphine (BUP) and Buprenorphine/Naloxone Combination (BUP -NX) 
Buprenorphine (BUP) is a lipophilic thebaine derivative with a high binding affinity at the mu -
opi[INVESTIGATOR_9744], and at the kappa opi[INVESTIGATOR_9745] a 
competitive antagonist.  Like many opi[INVESTIGATOR_9746].  In October 2002, the FDA approved BUP for  detoxification and maintenance 
treatment of opi[INVESTIGATOR_2561].  For these indications BUP is marketed as Subutex¬Æ (Reckitt 
Benckiser), and in a 4:1 ratio combination with naloxone (BUP -NX), as Suboxone¬Æ (Reckitt 
Benckiser).  The BUP -NX combination was developed to limit abuse liability and diversion.18-22  
Generic formulations of BUP -NX are now available. R ecently Reckitt Benckiser began 
marketing a sublingual BUP -NX film  and this is the formulation that is used in the present study .  
Numerous clinical trials, many of them conducted through a NIDA/VA Cooperative Studies Program partnership and others by [CONTACT_9853], involving thousands of 
participant s, have overwhelmingly established both efficacy and effectiveness of BUP -NX in the 
community.
21,23-32  BUP and BUP -NX are safe and effective alternatives to methadone27,28,30,33-36, 
and enable significant and substantial improvement over time in psychosocial functioning.37   
14 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9147] been safely administered for a period of up to a year.27,34,38    Variability 
in individual dosing addresses the range and severity of opi[INVESTIGATOR_9747].  
Because of BUP‚Äôs lipophilicity and high affinity to the mu- opi[INVESTIGATOR_9736], less -frequent -than-
daily dosing is possible for some patients.39   BUP‚Äôs slow dissociation from mu -opi[INVESTIGATOR_9748] -to-day course, and minimizes 
symptoms and signs of withdrawal upon cessation.40,[ADDRESS_9148] properties.38, 45- 5138,44 
Although there is a ceiling on BUP‚Äôs respi[INVESTIGATOR_9749]38, interactions with other 
CNS depressants such as benzodiazepi[INVESTIGATOR_9750]52,[ADDRESS_9149] BUP 
levels.  Known inhibitors include erythromycin, ketoconazole, grapefruit juice and certain HIV protease inhibitors
56 which may increase BUP levels.  Inducers include phenobarbital, 
carbamaz epi[INVESTIGATOR_050], and phenytoin which could reduce BUP levels and lead to withdrawal 
symptoms54 though this has not been observed clinically.   
Unlike methadone, BUP- NX is typi[INVESTIGATOR_9751]- based treatment settings which 
makes it an ideal comparator for XR-NTX, particularly at a time when there is a movement to 
expand treatment from traditional addictions specialty programs to mainstream healthcare settings.  Office -based BUP -NX permits patients to receive medication by [CONTACT_9854], weeks or even months, thereby [CONTACT_9855] 
(often daily) attendance at methadone maintenance programs and its associated stigma.  
Patients can return to a more "normal" life in a relatively short time span.  BUP -NX treatment 
may either be long or short term, however much of the available evidence (much of it from CTN studies
32,57 -59) suggests a high rate of relapse on discontinuation even after several months of 
treatment.  Many participants in CTN studies have expressed the strong desire to use BUP -NX 
as a maintenance medication rather than a short -term treatment or a detoxification agent.32, [ADDRESS_9150] implemented sustainable outpatient 
addictions pharmacotherapy initiatives with BUP -NX.   
Prescribing and Safety: Details on BUP -NX (Suboxone¬Æ) prescribing, pharmacokinetics and 
pharmacodynamics, metabolism and elimination, safety and toxicity are in Appendix D.  
4.[ADDRESS_9151] that approximately 50% of patients started on buprenorphine will be retained in treatment after six months, a good result for a chronic relapsing disorder such 
15 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
as opi[INVESTIGATOR_2561]; but the flip side of this is that  50% will have dropped out.  Further, 
despi[INVESTIGATOR_9752], ‚Äúnegative‚Äù views about agonist -based maintenance therapy persist 
amongst many individuals and institutions in the broader community and amongst many 
patients and providers who prefer a ‚Äúdrug- free‚Äù approach (i.e., free of narcotic or addictive drugs 
such as methadone, BUP or BUP -NX; in this context ‚Äúdrug- free‚Äù does not equate to 
‚Äúmedication -free‚Äù, for example non- addictive medication such as XR -NTX).  For institutions and 
individuals preferring ‚Äúdrug -free‚Äù treatment, XR -NTX may be a potent tool in facilitating 
‚Äúmedication -assisted recovery‚Äù.  
CTN- 0051 has the potential to:  (1) address critical clinical questions, (2) foster adoption of new 
pharmacotherapi[INVESTIGATOR_9753] -based specialty and mainstream treatment settings, and (3) 
advance public health (opi[INVESTIGATOR_9724], associated infections, associated criminal justice 
consequences, direct and indirect costs of addiction, etc.) by [CONTACT_9856].  
16 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
5.0 CTN-0051 OBJECTIVES  
5.1 Primary Objective  
The primary goal of the study is to estimate the difference, if one exists, between XR -NTX and 
BUP-NX in the distribution of the time to relapse (i.e., loss of persistent abstinence) during the 
6-month trial.  
The primary outcome measure is the time to the event , with the event called relapse. By 
[CONTACT_9857]. Relapse occurs if the participant 
is using any non- protocol prescribed opi[INVESTIGATOR_9754] [ADDRESS_9152] -randomization or 
thereafter.  Operationally, relapse is defined as either: (a) four consecutive opi[INVESTIGATOR_9755], or 
(b) seven consecutive days of use by [CONTACT_6270] -report.   A use week is defined as any week during 
which a participant self-reports at least one day of use during that week, provides a urine 
sample positive for non -protocol opi[INVESTIGATOR_2438], or fails to provide a urine sample.   Self-report of opi[INVESTIGATOR_2480] 
(heroin or prescription opi[INVESTIGATOR_2438]) and other substance use is ascertained at each weekly study 
visit using the Time line Follow -Back for each day leading back to the previous visit.   Urine is  
collected at each study visit and tested for opi[INVESTIGATOR_2438].   In the event that a participant reports no 
use, but their urine test indicates use, the week is considered a use week.    Missing urine 
samples are classified as positive. The time of the event occurs at the start of the qualifying 
clinical event period (e.g., first of the 7 consecutive use days or start of the 4 consecutive weeks of use).  
5.2 Secondary Objectives 
Secondary objectives are to:  
1. Comp are outcome on XR -NTX versus BUP -NX for the following domains:  
a. Proportion successfully inducted onto assigned medication.  
b. Safety, as measured by [CONTACT_9858], including opi[INVESTIGATOR_9756], both during the 6 -month trial and during the 3-month follow -up 
period.  
c. Opi[INVESTIGATOR_9757], as measured by [CONTACT_9859] -Back (TLFB) (self -report days 
using opi[INVESTIGATOR_2438]), proportion of opi[INVESTIGATOR_2480]- positive urine tests . 
d. Misuse of alcohol and other drugs of abuse (e.g., cocaine, other stimulants, cannabis, benzodiazepi[INVESTIGATOR_1651]) , by [CONTACT_6270] -report and urine drug screens.  
e. Tobacco use , as measured by [CONTACT_9860]√∂m Test for Nicotine Dependence (FTND) . 
f. Craving for opi[INVESTIGATOR_2438], and for other drugs, measured by [CONTACT_9861] (VAS).  
g. Depressive, anxiety, and subacute withdrawal symptoms (typi[INVESTIGATOR_9758], 
anorexia, and insomnia) , as measured by [CONTACT_9862] (17- item) 
(HAM -D) and the Subjective Opi[INVESTIGATOR_9721] (SOWS). 
h. Problems related to drug abuse, as measured by [CONTACT_9863] -Index -Lite (ASI -
Lite) and EuroQ ol (EQ-5D). 
i. HIV risk behavior over time, as measured by [CONTACT_9864] (RAB).  
j. Cognitive function, as measured by [CONTACT_9865] ( Trail 
Making Test Parts A and B , Stroop ). 
2. Explore baseline demographic , clinical, and genetic  features as predictors of opi[INVESTIGATOR_9759] 6- month trial (main effect of predictors), and as moderators of differential 
treatment effect (moderator by [CONTACT_9866]).  
3. Collect a limit ed dataset to permit analyses of economic costs and benefits of the two 
treatments.  
17 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
6.0 STUDY DESIGN  
6.1 Overview of Protocol Study Design 
This is a multi- center, two -arm, 6 -month (24 -week), parallel- group, open- label, randomized 
controlled trial to examine the comparative effectiveness and safety of XR -NTX versus BUP -NX.  
Candidates are  individuals seeking treatment for opi[INVESTIGATOR_2561] (heroin or prescription 
opi[INVESTIGATOR_2438]) who are admitted to an inpatient (detoxification and/or short term residential treatment) 
program for treatment of substance dependence. The study is conducted in 8 CTPs that: (a) 
provide or partner with opi[INVESTIGATOR_9760] (inpatient/residential)  which have the 
capacity to maintain participants opi[INVESTIGATOR_2480]- free, ( b) have the capacity to initiate patients onto XR -
NTX or BUP -NX, ( c) have the capacity to maintain participants on XR -NTX or BUP -NX for the 
duration of the 24-week trial, ( d) have a sufficient flow of patients completing detoxification and 
who do not routinely receive long -term medication- assisted therapy as to provide a sufficient 
population of potential participants to achieve study enrollment goals, and ( e) can provide a 
minimum level of outpatient care (at least one group and/or individual counseling session per week) for 24 weeks.  Candidates are consented, screened, and randomized at the time of 
admission, during detoxification or during early abstinence.  Participants meeting all eligibility criteria are randomized to one of two treatment conditions, XR -NTX or BUP -NX.  Treatment is 
for 24 weeks in the context of a protocol -directed medical management treatment program and 
individual or group psychosocial  counseling .  Research visits occur weekly , until relapse criteria 
are met,  for collection of urine samples and safety and other assessments.  XR -NTX is 
administered by [CONTACT_9867] -four-week basis; BUP- NX is  provided for 
take-home, initially on a weekly basis, transitioning to an every -two-week and then to an every -
four-week schedule.  Medical management for both conditions is on a similar (weekly , 
transitioning to every -two-weeks, to every -four-weeks) schedule.  The primary outcome 
measure is the time to the event of relapse.  XR -NTX is provided as Vivitrol
¬Æ.  BUP -NX is  
provided as Suboxone¬Æ  film. 
The Protocol will proceed in four phases (see Figure 1 ). 
Phase 1: Informed Consent, Screening, and Randomization (Days -15 through Day 0) : This 
phase begins with informed consent during the index admission, and initiates enrollment, the conduct of all study -specific procedures and the collection of study data.  During the first several 
days of an index admission, clinical and/or research staff provide information about the study to potential participants (for scheduled admissions this information may be provided in advance of 
the admission).  Guidelines for opi[INVESTIGATOR_9761]; data on 
detoxification utilization are collected.  This phase may take place from [ADDRESS_9153], the date of randomization is defined as ‚ÄúDay 0‚Äù.  
Phase 2: Induction (Day 0 through Day 156): Following randomization, pa rticipants are inducted 
onto their assigned active medication condition and treated as outpatients for 24 weeks per protocol.  Guidelines for induction onto XR -NTX and onto BUP- NX are provided in the study 
MOP.  Following induction, XR -NTX is administered by [CONTACT_9868] 4 weeks; 
and BUP -NX is  quickly titrated upwards to maintenance doses.  Induction should occur as soon 
as practicable following randomization, but may occur as late as week 22. Participants continue 
into Phases 3 and 4 for research visits, even if not yet inducted onto their assigned medication.  
Phase 3: Active Treatment ( Week 1  through Week 24) : Following randomization, participants 
are inducted as soon as practicable and treated per their assigned active medication condition  
18 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9154] -randomization.  Assessment visits occur weekly  
until relapse criteria are met.  Participants whose induction onto their assigned study medication 
is delayed will also attend weekly research visits.  Medical management visits will initially occur 
weekly, transition to every two weeks and then to every four weeks.   In order to retain 
participants in treatment, and consistent with good practice, we permit flexibility with dosing (see 
section 8.5).   The window for Visit 1 is -3/+6 days to accommodate induction; however , 
induction may occur after Visit 1.  A +/- 3-day window is permissible for subsequent  weekly 
visits.  For participants who relapse and/or become lost to follow up, a -3/+28 day  window is 
permissible to complete the EOT visit.  Participants who relapse will discontinue study 
medication and weekly research visits, but should be encouraged to attend the week 24 and 
follow up visits at weeks 28 and 36.  
Phase 4: Post Treatment Follow -up (Week 25 through We ek 36): Toward the end of the 24 -
week treatment period, participants are referred for follow -up care in the community  (which 
could include continuation of medication, if available, indicated, and desired),  and follow -up 
outcomes are assessed at week [ADDRESS_9155]-randomization.  For participants receiving 
BUP-NX, who do not wish to continue, or for whom community resources are not available, the 
study provides a two -week BUP -NX taper .  A -3/+28 day  window is  permissible for the 
scheduled week  28 visit and a +/- [ADDRESS_9156] therapy is unknown.  A risk to 
this study plan is that a differentially large percentage of individuals may be unable to initiate XR-NTX versus buprenorphine therapy. The study includes an adaptive strategy such that if a t a 
single time point a statistically lower treatment initiation rate is observed in ‚Äúearly‚Äù entry cases, then the study will be revised to: 
(a) Exclude further early entry cases and analyze them separately; and  
(b) Expand the total accrual target to maintain the initial design power for the late entry cases. 
This assessment occur red after the entry of 100 cases randomized early in the detoxification 
process (e.g., prior to 3 opi[INVESTIGATOR_2480]- free days).  
6.3 Duration of Study and Visit Schedule  
Each participant is engaged in the overall study for approximately 9 months as follows:  
‚Ä¢ Up to 15 days: Consent, screening  and randomization. 
‚Ä¢ 24 weeks: Weekly research visits  for 24 weeks ; and active treatment , once inducted , 
up to week [ADDRESS_9157]-randomization. 
‚Ä¢ 12 weeks: Follow -up, with visits at weeks [ADDRESS_9158]-randomization.  
19 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
7.0 STUDY POPULATION  
Study participants are treatment -seeking heroin - and/or prescription opi[INVESTIGATOR_2480]- dependent 
volunteers, without chronic pain requiring opi[INVESTIGATOR_2538], who are willing to accept  ‚Äúagonist -
based‚Äù or ‚Äúantagonist -based‚Äù therapy.  Randomization is stratified by (1) treatment site, and (2) 
baseline opi[INVESTIGATOR_2441] (high level use [‚â•6 bags {or equivalent } IV heroin/day] vs. all others [i.e., <6 
bags {or equivalent } IV heroin/day  and other routes of administration or other opi[INVESTIGATOR_2438] ]).   
7.1 Inclusion Criteria  
1. Male or female;  
2. 18 years of age and older;  
3. Meet DSM -5 criteria for opi[INVESTIGATOR_2480]- use disorder  (heroin and/or prescription opi[INVESTIGATOR_2438]) ; 
4. Have used opi[INVESTIGATOR_9762];  
5. Seeking treatment for opi[INVESTIGATOR_9763] ‚Äúagonist -based‚Äù or 
‚Äúantagonist -based‚Äù therapy;  
6. In good -enough general health, as determined by [CONTACT_9869], review of systems, physical exam and laboratory assessments, 
to permit treatment with XR -NTX or BUP -NX; 
7. Able to provide written informed consent ; 
8. Able to speak English sufficiently to understand the study procedures and provide 
written informed consent to participate in the study ; 
9. If female of childbearing potential, be willing to practice an effective method of birth control for the duration of participation in the study . 
7.2 Exclusion Criteria  
1. Serious medical, psychiatric or substance use disorder that, in the opi[INVESTIGATOR_9764], would make study participation hazardous to the participant or 
compromise study findings or would prevent the participant from completing the 
study. Examples include:  
(a) Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end -stage liver disease) as assessed by [CONTACT_9870], review of 
systems, physical exam and/or laboratory assessments;  
(b) Severe, untreated or inadequately treated mental disorder (e.g., active 
psychosis, uncontrolled manic -depressive illness) as assessed by [CONTACT_9871]/or clinical interview;  
(c) Current severe alcohol, benzodiazepi[INVESTIGATOR_050], or other depressant or sedative 
hypnotic use likely to require a complicated medical detoxification (routine 
alcohol and sedative detoxifications may be included) ; 
2. LFTs (ALT, AST) greater than 5 times upper limit of normal;  
3. Suicidal or homicidal ideation that requires immediate attention;  
4. Known allergy or sensitivity to buprenorphine, naloxone, naltrexone, polylactide-co-
glycolide, carboxymethylcellulose, or other components of the Vivitrol
¬Æ diluent;  
5. Maintenance on methadone at doses of 30mg or greater at the time of signing 
consent;  
6. Presence of pain of sufficient severity as to require ongoing pain management with opi[INVESTIGATOR_2438];  
7. Pending legal action or other reasons that might prevent an individual from 
completing the study;  
8. If female, c urrently pregnant or breastfeeding, or planning on conception;  
20 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
9. Body habitus that, in the judgment of the study physician, precludes safe 
intramuscular injection of XR -NTX (e.g., BMI>40, excess fat tissue over the 
buttocks, emaciation).  
7.2.1 Special Populations to Consider  
This study is likely to enroll persons involved in the criminal justice system, many of whom are 
expected to be in treatment at the CTPs conducting this study.   The study will not recruit 
persons incarcerated/detained in a correctional facility, but will not exclude parolees, 
probationers, or persons in sentencing diversion or drug court programs who are enrolled at 
participating CTPs.  Some of these subjects may be classified as prisoners per 45 CFR 46 
Subpart C.  
7.3 CTP Sites  
This multi- site trial involve s 8 CTPs that: (a) provide or partner with opi[INVESTIGATOR_9760] 
(inpatient/residential)  which have the capacity to maintain participants opi[INVESTIGATOR_2480]- free, ( b) have the 
capacity to initiate participant s onto XR -NTX or BUP -NX while they are still in an 
inpatient/residential setting, ( c) have the capacity to maintain participants on XR -NTX or BUP -
NX for the duration of 24- week trial, ( d) have a sufficient flow of patients completing 
detoxification and who do not routinely receive long -term medication- assisted therapy as to 
provide a sufficient population of potential participants to achieve study enrollment goals, and 
(e) can provide a minimum level of outpatient care (at least one group and/or individual 
counseling session per week) for 24 weeks. 
21 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
8.0 STUDY PROCEDURES  
Refer to Figure 1 (Study Schema).  
8.1 Recruitment and Screening (Phase 1)  
Recruitment efforts will vary per site, and may broadly include CTP staff education and 
distribution of study materials, community or participant -level outreach and advertisements, and 
the encouragement of word- of-mouth referrals among CTP patient populations.  During (or prior 
to) the first several days of an index admission, clinical and/or research staff will provide information about the study to interested, potential participants.  
8.1.1 Informed Consent (Phase 1)  
At any point candidates may begin the informed consent and screening procedures.  The timing 
of consent and screening procedures is flexible, and allows CTPs to customize recruitment, 
screening, and randomization procedures to accommodate local conditions.  Obtaining consent and baseline data early in the admission will allow a full accounting of persons interested in 
study enrollment but then not choosing to or not able to enroll (screen fails), while enrollment 
towards the end or just after detoxification will allow participants initially exposed to enrollment 
to reconsider and join the trial several days later.  Candidates for the study are given a current 
local IRB -approved copy of the Informed Consent Form to read.  Appropriately qualified and 
trained study personnel explain all aspects of the study in lay language and answer all of the 
study candidate‚Äôs questions.  Candidates who remain interested after receiving an explanation of the study are given a short informed consent quiz to test his/her understanding of the project, 
the purpose and procedures involved, and the voluntary nature of his/her participation.  Those who cannot successfully answer quiz items have the study re- explained by [CONTACT_9872] a 
focus on aspects they did not understand. Those who demonstrate understanding of the study and voluntarily agree to participate are asked to sign the Informed Consent Form.  Participants 
will not be administered any assessments or study procedures prior to signing informed 
consent.  Participants are also asked to sign a release of medical records request to permit 
study staff to access CTP records relating to the index admission, prim arily for the purpose of 
accessing clinical laboratory information (e.g., liver function tests) to eliminate repeat testing and 
speed randomization.   
8.1.2 Detoxification  
Guidelines for protocol- guided opi[INVESTIGATOR_9734] (to be initiated after informed consent and 
depending on when in the detoxification process consent is obtained) are provided in the study 
MOP. Data on the detoxification, including number of days on the unit and medications 
received, are  collected.  
8.1.3 Screening and Baseline Assessments (Phase 1) 
Screening and baseline assessments are detailed in Section 11 and capture participant demographic, medical, psychiatric, drug use, and treatment history, quality of life and current 
health status, in addition to blood and urine testing.  These assessment s confirm 
eligibility/ineligibility.  Screening may take place at any time during Phase 1.  LFTs performed 
within 4 weeks prior to randomization (i.e., drawn as part of usual care) are acceptable.  If LFT 
results are available at screening, and participants meet all eligibility criteria, randomization may proceed.  Otherwise, final eligibility is determined upon confirmation of LFTs. 
22 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
8.2 Randomization (Phase 1, Day 0)  
Randomization follow s final confirmation of eligibility.  
While the timing of randomization can be variable, it is expected that each randomized 
participant will initiate his or her assigned treatment.  Success in initiating assigned treatment is 
tracked.  
8.3 Stratified Randomization  
A restricted randomization plan is used with centralized, automated,  randomized block 
assignments.  Randomization is stratified by [CONTACT_9873], site and pre- detoxification level of 
opi[INVESTIGATOR_2441].  While there are important and otherwise uncharacterized differences between sites 
‚Äì including state and local treatment service environments, opi[INVESTIGATOR_9765], and 
patient -level customs regarding treatment, medications, and clinical trial participation ‚Äì the level 
of heroin and other opi[INVESTIGATOR_9766].60-62  The level of opi[INVESTIGATOR_9767] a binary classification, 
operationally defined as 6 or more bags (or equivalent ) IV heroin per day (‚â•6 bags/day) over the 
7 days prior to entry into the treatment program  versus less than 6 bags (or equivalent ) IV 
heroin per day (<6 bags/day ) or other routes of administration or other opi[INVESTIGATOR_2438] .   
Timing of the randomization is important to execution of the design and may also be an 
important prognostic variable. All cases are classified into one of three groups at the time of 
randomization, those:  
(a)  randomized within [ADDRESS_9159] (licit or illicit) opi[INVESTIGATOR_2441];  
(b)  randomized between [ADDRESS_9160] (licit or illicit) opi[INVESTIGATOR_2441] ; 
(c)  randomized more than [ADDRESS_9161] (licit or illicit) opi[INVESTIGATOR_2441].  
Each of these groups represents different clinical scenarios  common ly encountered in CTN 
CTPs . Group (a) represents early  decision- making, at such a time as to avoid unnecessary 
detoxification for those choosing BUP -NX.  For group (b) , decision- making occurs later during 
detoxification, but while participants  still need to surmount the detoxification hurdle to begin XR -
NTX.  Group (c) includes participants  who can be readily induc ted onto either medication.  
Individuals in groups (a) and (b) comprise the early cases used in the decision rule assessment after 100 of these participants  had entered.   
8.4 Induction (Phase 2)  
Following randomization, participants are inducted onto their assigned pharmacotherapy.  
Guidelines for detoxification and induction onto XR -NTX or BUP -NX are provided in the study 
MOP.  
XR-NTX assignment: participants randomized to XR- NTX must complete/have completed a 
recent opi[INVESTIGATOR_9734], be ‚â•[ADDRESS_9162] (heroin, prescription opi[INVESTIGATOR_2438], methadone or buprenorphine), have a urine toxicology negative for the 
extended opi[INVESTIGATOR_9768], including methadone and buprenorphine, and have a negative 
naloxone challenge.  
BUP-NX assignment: a) participants randomized during a buprenorphine- based detoxification 
will continue on buprenorphine, now as a daily maintenance dose.  BUP-NX will be titrated over 
1-3 days to a maintenance dose range of 8- 24mg/day . Lower doses and doses up to 32mg/ day 
may be prescribed with the approval of the site PI [INVESTIGATOR_9769]; b) participants 
randomized during a methadone -based detoxification will discontinue methadone, and be 
23 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9163] clearly emerged ; c) participants randomized during a non -opi[INVESTIGATOR_2480]-
based detoxification or after completing a bup renorphine- or methadone- based detoxification 
may be induc ted onto BUP -NX immediately  or after a sufficient delay since last methadone 
dose.  
8.5 Study Treatments (Phase 3)  
Table 1:  Treatment Visit Schedule  
Study Week  -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Medical Management Visits (both arms)   x x x x x  x  x  x  x  x  x    x    x 
XR-NTX Administration   x* x* Approximately every 4 weeks, with final injection occurring no later 
than week 22.    
BUP-NX Dispensing   x x x x x  x  x  x  x  x  x    x    x~ 
x*=the initial XR -NTX dose will depend on the length of time needed to complete detoxification and begin XR -NTX 
treatment; x~ = for BUP-NX taper where indicated  
A. Medical Management:  Both Arms  
Both groups receive Medical Management (MM) clinical support from the same study clinician s 
(e.g., MD, DO, PA, NP, RN; working within the scope of their local licensure, clinical privileges 
and/or scope of practice)  in unblinded fashion.  MM is adapted from several recent studies of 
NTX, XR -NTX and BUP -NX, including the NIAAA COMBINE study63, Krupi[INVESTIGATOR_9729].8, and CTN -
0030 (POATS).[ADDRESS_9164] of a 
trial‚Äôs psychosocial interventions (i.e., the COMBINE trial or CTN -0030, POATS), and in keepi[INVESTIGATOR_9770] a pragmatic, community -based comparative effectiveness trial, MM is broadly guided by  
[CONTACT_9874], a common progress note and 
the MM MOP, but is not subject to rigorous quality assurance procedures (i.e., audiotapi[INVESTIGATOR_007], 
manualization and QA audits).  The study clinician assesses  concomitant medications at each 
medical management visit.  As this is not an IND study, and both medications are FDA approved for opi[INVESTIGATOR_2561], the study data capture system does not include a concomitant 
medication case report form.  MM visit schedu les are the same for both arms, initially weekly 
(week s 0-4), then every two weeks (weeks 4- 16), and finally every four weeks (weeks 16, 20, 
24).  XR -NTX is  injected at the MM visit approximately every [ADDRESS_9165] on week 24 although no medication is dispensed 
(except for BUP -NX taper where this is indicated).  
B. Psychosocial Counseling: Both Arms  
Psychosocial counseling consist s of outpatient counseling provided at the CTP. Selected sites 
agree to provide at least a minimum level of outpatient care that consists of at least one group and/or individual counseling session per week for up to [ADDRESS_9166] or from the participant on counseling sessions attended.  Participation in counseling sessions is voluntary.  Failure to attend counseling sessions will not be considered 
to be a reason to be excluded from the tri al. 
24 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9167] complete/have 
completed a recent opi[INVESTIGATOR_9734], be ‚â•[ADDRESS_9168] (heroin, prescription opi[INVESTIGATOR_2438], methadone or buprenorphine) and have a urine toxicology 
negative for all opi[INVESTIGATOR_2438], including buprenorphine.  If initial UDS is positi ve, UDS is repeated daily 
until negative.  Only then will the naloxone challenge take place. 
[IP_ADDRESS]  XR-NTX Injections 
Following a negative naloxone challenge (see MOP), XR -NTX monthly injections begin.  XR-
NTX ( 4cc, ~380mg of naltrexone base) is administered approximately every four weeks  (with 
the final injection occurring no later than week 22),  in the form of Vivitrol¬Æ which is obtained by 
[CONTACT_9875].   XR-NTX injections may take place <4 
weeks apart if there is clinical concern about non- adherence ( participant is inconsistent in 
attending scheduled visits) or if clinical observation is that opi[INVESTIGATOR_9771]/or use re- emerge 
during the 4th week after the last injection; however, time between injections must always be at 
least 21 days.  XR-NTX is administered by [CONTACT_9876] (alternating 
sides) according to the injection preparation and administration procedures specified in the Vivitrol
¬Æ product package insert (see Appendix C).  These procedures are designed to minimize 
the risk of injection site reactions.   
[IP_ADDRESS]  Ancillary Medications  
Participants who experience withdrawal symptoms, sleeplessness, and/or depressive symptoms 
may be treated with ancillary medications (see guidelines in the study MOP).  Depression is 
common in opi[INVESTIGATOR_2480]- dependent patients and may adversely affect prognosis of naltrexone 
treatment.60  Participants who show depressive symptoms may be treated with antidepressants 
and/or referred for psychiatric evaluation and treatment.  In general, psychiatric or medical problems emerging during the study treatment period are handled by [CONTACT_9877].   
[IP_ADDRESS]  Handling of Missed XR -NTX Doses, Lapses, and Relapses  
Use of illicit opi[INVESTIGATOR_9772] -
NTX maintenance, compared to those receiving BUP -NX.  Because of the long duration of 
action of XR -NTX (full blockade out to [ADDRESS_9169] injection
17), a grace period of 7 -21 
days can be expected during which the injection can be rescheduled, provided the participant 
has not relapsed and become re -dependent.  If the participant misses a scheduled injection and 
does not otherwise meet the primary outcome of relapse, XR -NTX may then be continued 
following a negative naloxone challenge (if cli nically indicated) up to 21 days after a missed 
dose ([ADDRESS_9170] prior injection; see MOP).    
8.5.2 BUP-NX Group  
In keepi[INVESTIGATOR_9773], BUP -NX treatment is initiated as soon as 
practicable following consent, determination of eligibility, and randomization.  Guidelines for 
induction at varying times from early in detoxification through early abstinence are provided in 
the study MOP.  See also Section [IP_ADDRESS], titled ‚ÄúBUP -NX Induction‚Äù.  
25 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
[IP_ADDRESS]  BUP-NX Medication  
BUP-NX is  provided as Suboxone¬Æ  sublingual film, 4mg/1mg of buprenorphine/naloxone, or 
8mg/2mg buprenorphine/naloxone to allow individualized medication plans.  Medication is 
provided by [CONTACT_9875].  
[IP_ADDRESS]  BUP-NX Induction  
a) Participants randomized during a buprenorphine -based detoxification simply continue on 
buprenorphine (as BUP -NX).  Doses may be escalated rapi[INVESTIGATOR_375], and titrated to a maintenance 
dose of 8- 24mg/day over 1- 3 days.  Lower doses and doses up to 32mg per day may  be 
prescribed with the approval of the site PI [INVESTIGATOR_9769].  See guidelines in the study 
MOP.  
b) Participants randomized during a methadone- based detoxification discontinue methadone, 
and are induc ted onto BUP -NX no less than 24hours following the last methadone dose.  See 
guidelines in the study MOP.  
c) Participants randomized during a non -opi[INVESTIGATOR_2480]- based detoxification or after completing a 
buprenorphine- or methadone- based detoxification, who are thus ‚Äúdrug -free‚Äù, are given an initial 
4mg/1mg sublingual  dose, followed by [CONTACT_9878], and thereafter titrated  up to a 
maximum dose of 16mg on day 1, and a maintenance dose of 8 -24mg/day over day s 2-7.  See 
guidelines in the study MOP.  
[IP_ADDRESS]  BUP-NX Maintenance  
Maintenance doses of BUP -NX from 8mg-24mg are typi[INVESTIGATOR_9774].  Lower 
dose and doses up to 32mg per day may be prescribed with the approval of the site PI [INVESTIGATOR_9775].  For all BUP -NX participants, from induction through week 24,  daily doses may 
be titrated to minim ize BUP -NX related AEs, minimize cravings, and in response to any 
intermittent illicit opi[INVESTIGATOR_2441]/lapse.  
8.5.3 Dispensing of XR -NTX and BUP -NX 
Study medications (XR -NTX and BUP -NX) are provided by [CONTACT_9879].  XR -NTX is administered in -clinic at induction and approximately every four weeks 
with the final injection occurring no later than week 22.   BUP-NX is  dispensed to participants at 
induction and at treatment weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, and 20.  Medication may be 
dispensed more frequently at the discretion of the study clinician.  In addition, for participants 
receiving BUP -NX who are discontinued, who do not wish to continue, or for whom community 
resources to continue are not available, the study may dispense sufficient BUP- NX for up to a 
two-week taper beginning at any time during treatment  or beginning at the week 24 visit.  BUP -
NX dose adjustments or emergency medication replacement between visits are allowed and wi ll 
necessitate as -needed treatment and medication- dispensing visits.  The clinical team may 
extend the window for medication administration or dispensing by [CONTACT_9880] (a) the 
participant is abstinent (both self -report and urine are negative), (b) can restart the originally 
assigned medication, and (c) the treatment lapse is scheduled (i.e., the participant has provided 
a credible reason for the lapse and remains in contact [CONTACT_9881]).  
[IP_ADDRESS]  Provisions for Access to Investigational Treatment After Study  
Prior to the conclusion of the 24- week active treatment phase, the research team will make an 
effort to arrange for continued treatment with XR -NTX or BUP -NX as appropriate within the 
community context.  Where this is not possible (due to insurance or availability of treatment resources, etc.), alternative treatment referrals (i.e., methadone maintenance, intensive 
26 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
outpatient psychosocial aftercare) are made as appropriate.  For participants receiving BUP -NX, 
who do not wish to continue, or for whom community resources are not available, the study 
provides a two -week BUP -NX taper.  
8.6 Drug Packaging/Handling/Storage/Accountability  
8.6.1 Study Medication Management  
Each CTP is required to observe local, state, and federal regulations regarding receipt, custody, dispensing, and disposition of all study medications . Each  CTP will maintain an adequate supply 
of unexpi[INVESTIGATOR_9776].  
8.6.2 Drug Accountability Records and Dispensing of Study Medication  
Appropriately qualified and trained study personnel maintain accurate and current accounting of 
all study medication by [CONTACT_9882].  
 Accurate drug accountability records:  
‚Ä¢ Demonstrat e that the study drug was dispensed according to the protocol ; 
‚Ä¢ Document receipt of the study medication, date, lot #, expi[INVESTIGATOR_320], quantity and dosage ; 
‚Ä¢ Account for unopened, un- dispensed, unused, returned, waste or broken medication; 
‚Ä¢ Dosing logs should record participant  ID #, date dispensed, drug name, lot # and amount 
dispensed; 
‚Ä¢ Temperature logs should show a daily record of medication storage temperature . 
8.6.3 Study Medication Storage  
Study medication should be stored in compliance with federal, state, and local laws and 
institutional policy. Study medication is stored in a secured location under the conditions 
specified by [CONTACT_9883] s (See Appendices C and D). 
8.6.4 Used/Unused Medication  
Study medication returned by a participant may not be re- issued for use.  Unused study 
medication is returned and logged into a perpetual inventory of study medication returned. 
Damaged, returned, expi[INVESTIGATOR_9777] a reverse distributor for destruction. Expi[INVESTIGATOR_9778] -
NTX may be destroyed on site per local institutional policies following a complete accounting by 
[CONTACT_9884] . 
8.6.[ADDRESS_9171] or licensed medical practitioner appropriately trained and authorized to dispense study medications per local 
regulations.  
27 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
8.6.7 Drug Packaging  
XR-NTX is supplied in single use kits. Each kit will contain one 380 mg vial of Vivitrol¬Æ 
microspheres, one vial containing 4 mL (to deliver 3.4 mL) diluent for the suspension of Vivitrol¬Æ, 
one 5- mL prepackaged syringe, one 1- inch [ADDRESS_9172] incentives for attending study visits.  This study 
does  not employ contingency management targeting abstinence or specifically targeting 
medication adherence (in other words, compensation is earned for presenting to scheduled 
visits and completing assessments and medication management visits if applicable).  
 
Participants receive $50 for completion of screening  and baseline assessments and an 
additional $50 following induction onto study medication.  Participants receive $20 for each weekly visit for weeks 1 through 23.  Participants receive $50 for visit 24 and each of the 2 
follow -up visits.  Maximum compensation possible is $710.   If a participant is found to be 
incarcerated at time of follow -up, the participant is compensated the agreed upon amount as 
approved by [CONTACT_9885]/or collaborating prison facilities.   
 
28 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
9.0 OUTCOME MEASURES  
9.1 Primary Outcome  
The primary goal of the study is to estimate the difference, if one exists, between XR -NTX and 
BUP-NX in the distribution of the time to relapse (i.e., loss of persistent abstinence) during the 
6-month trial.  
The primary outcome measure is the time to the event , with the event called relapse. By 
[CONTACT_9857]. Relapse occurs if the participant 
is using any non- protocol prescribed opi[INVESTIGATOR_9754] [ADDRESS_9173] -randomization or 
thereafter.  Operationally, loss of persistent abstinence is defined as either: (a) four consecutive 
opi[INVESTIGATOR_9755], or (b) seven consecutive days of use by [CONTACT_6270] -report.   A use week is defined as 
any week during which a participant  self-reports at least one day of use during that week, 
provides a urine sample positive for non- protocol opi[INVESTIGATOR_2438], or fails to provide a urine 
sample.   Self-report of opi[INVESTIGATOR_2480] (heroin or prescription opi[INVESTIGATOR_2438]) and other substance use is 
ascertained at each weekly study visit using the Timel ine Follow -Back for each day leading back 
to the previous visit.   Urine is  collected at each study visit and tested for opi[INVESTIGATOR_2438].   In the event 
that a participant reports no use, but their urine test indicates use, then the week is considered a 
use week.   Missing urine samples are classified as positive. The time of the event occurs at the 
start of the qualifying clinical event period (e.g., first of the 7 consecutive use days or start of the 4 consecutive weeks of use).  
9.2 Secondary Outcomes  
Table 2:  Protocol Secondary Outcomes and Hypotheses 
Outcomes  Hypotheses  
Proportion successfully inducted 
onto assigned study medication 
(binary: did or did not receive first 
dose of XR -NTX, or achieve 
maintenance dose of BUP -NX) BUP- NX will produce higher rate of successful induction than XR -
NTX 
Significance/Rationale: XR -NTX induction requires completion of 
detoxification, whereas BUP -NX induction only requires onset of 
withdrawal symptoms. Thus XR -NTX may have more dropouts 
after randomization but prior to XR -NTX induction.  
Adverse Events related to study 
medications XR-NTX and BUP -NX will produce equivalent rates of SAEs, and 
equivalent rates of AEs, though AE pattern will differ somewhat 
(e.g. injection site reactions with XR -NTX)  
Significance/Rationale: Careful documentation of SAEs and AEs, 
including overdose epis odes, would be considered essential 
safety data, and important component of a comparative 
effectiveness trial.  
Opi[INVESTIGATOR_9779] (Weekly 
TLFB, confirmed by [CONTACT_9886])  
 XR-NTX will produce greater opi[INVESTIGATOR_9780] -NX  
Significance/Rationale: XR -NTX produces complete blockade of 
opi[INVESTIGATOR_9781], so that during treatment with monthly injections, 
opi[INVESTIGATOR_9782].  In contrast BUP -NX 
may not produce complete blockade, or patients may  reduce or 
stop doses for a few days and substitute other opi[INVESTIGATOR_2438] (heroin, 
prescription opi[INVESTIGATOR_2438]).  
29 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
Outcomes  Hypotheses  
Alcohol and other drug use, over 
time (TLFB and UDS)  XR-NTX will be superior to BUP- NX in producing abstinence from 
alcohol and other drugs  
Significance/Ra tionale: Clinical trials show XR -NTX is effective 
for treatment of alcohol dependence, and naltrexone has some 
evidence of efficacy for stimulant dependence. 
Cigarette smoking (FTND , 
Tobacco Use Questionnaire, VAS 
nicotine craving) XR-NTX will reduce cigarette smoking compared to BUP -NX  
Significance/Rationale: Naltrexone has been studied as a 
treatment for nicotine dependence , with some support from 
clinical trials, although inconsistent.  Given high morbidity and 
mortality associat ed with nicotine dependence , a comparative 
advantage of one or the other of these treatments at reducing 
smoking would be valuable to examine.  
Opi[INVESTIGATOR_2516] (VAS) over time  XR-NTX will be superior to BUP- NX in reducing opi[INVESTIGATOR_9783]/Rationale: Krupi[INVESTIGATOR_9729] . (Lancet 2011) pi[INVESTIGATOR_9784] -
NTX trial showed, surprisingly, that XR -NTX reduced craving 
substantially compared to placebo.  
Subacute withdrawal symptoms 
over time (HAM- D, SOWS)  XR-NTX will produce greater severity of s ubacute withdrawal 
symptoms than BUP -NX during the first month after 
randomization, but will be equivalent to BUP -NX in months 2 to 6  
Significance/Rationale: Low -grade withdrawal -like symptoms 
(dubbed ‚Äúnaltrexone flu‚Äù by [CONTACT_9887], and consisting 
typi[INVESTIGATOR_9785], fatigue, and anorexia, though not drug 
craving) have been observed in some patients in the 1 to 4 
weeks after naltrexone initiation, resolving gradually.  Further 
characterization of this syndrome would be important for 
developi[INVESTIGATOR_9786].  
Problems related to drug abuse  
(ASI-Lite and EQ -5D) XR-NTX will be superior to BUP- NX 
Significance/Rationale: Greater opi[INVESTIGATOR_9787]- opi[INVESTIGATOR_9788] -NTX will result in fewer  problems associated with active 
drug abuse.  
HIV ri sk behavior over time (RAB  
and other HIV risk measures ) 
 
 XR-NTX and BUP -NX will be equivalent  
Significance/Rationale: The opi[INVESTIGATOR_2480]- dependent population is at 
high risk for HIV, both from injection drug use and from unsafe 
sexual practices.  Effective treatment for the opi[INVESTIGATOR_9789]. Given the high morbidity and 
mortal ity associated with HIV, a comparative advantage of one or 
the other of these treatments would be valuable to examine.  
Cognitive function ( Trails  Making 
Test Parts A and B, Stroop)  
 XR-NTX and BUP -NX will be equivalent  
Signif icance/Rationale:  Some providers and policy -makers are 
concerned that patients maintained on BUP -NX will have opi[INVESTIGATOR_2480] -
agonist -related cognitive impairment.  
30 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
10.0 PARTICIPANT DISCONTINUATION, FOLLOW -UP 
10.1 Treatment Discontinuation  
Study medication is discontinued in the event of intolerable side effects, safety concerns 
preventing further medication treatment (i.e., pregnancy), relapse, or the end of the 24- week 
active treatment phase (see MOP).  Participants discontinuing medication , but not yet meet ing 
relapse criteria, prior to week 24 continue within the same study assessment schedule . 
Participants meeting relapse criteria discontinue medication and research visits.  All  participants 
who end treatment early (prior to week 21) are encouraged to attend a visit at week 24 and are 
seen in long -term follow -up (weeks 28 and 36 ).  In all cases of treatment discontinuation, the 
research team makes an effort to arrange for continued community treatment, as appropriate 
and available, including further XR -NTX and BUP -NX, or methadone maintenance and intensive 
outpatient psychosocial aftercare.  For participants receiving BUP -NX, who do not wish to 
continue, or for whom community resources are not available, the study will provide a two- week 
BUP-NX taper , if cli nically appropriate.    
10.2 Follow-Up (Phase 4)  
An effort will be  made to assess a ll participants  at weeks [ADDRESS_9174] randomization. The 
goals for the follow -up assessments are as follows:  
A. Assess safety in initial weeks and months following discontinuation of XR -NTX or BUP -
NX.  This would specifically address concerns about overdose deaths after XR -NTX and 
the criticism leveled at the FDA for approving XR -NTX indication without such data.   
B. Determine 9- month outcome following randomization to up to six month s of treatment 
with XR- NTX or BUP -NX, including rates of relapse after successful completion of [ADDRESS_9175] treatment  and whether 
there are differences in long -term outcomes; it will address whether early gains are 
sustained across time; and it will provide descriptive data on the course of opi[INVESTIGATOR_9790].  
C. Learn about what interventions are currently available and can be accessed in the community outside of a research study. This would address questions about what is current TAU for opi[INVESTIGATOR_2561]. 
Aggressive outreach procedures will be implemented to locate and assess participants at the [ADDRESS_9176] be compliant with 45 CFR 46 Subpart C.   Data may be collected either in person, by [CONTACT_648], in writing, and/or by [CONTACT_471], provided that data collection follows the procedures approved by [CONTACT_9888].  Details of the nature of the research will not be shared with staff at the jail/prison, and 
visits, whether in person or by [CONTACT_648], will only be conducted if the participant‚Äôs confident iality 
can be maintained and no audio- tapi[INVESTIGATOR_4095].  
31 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9177] as efficiently as possible, 
minimizing the time and expense of research visits.  Table 3 is a schedule of procedures and 
assessments (note that some study procedures are described in Section 8).  
32 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
Table 3:  Schedule of Forms, Procedures and Assessments 
 Screening Baseline RandomizationInduction
XR-NTXInduction
BUP-NXEnd of 
Study (if 
not wk 36)
Visit# S B 0 IND-X IND-B 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 EOM6EOT 28 36 EOS
Time          Day -10 to 0 0 Day 0-156 Day 0-156 613 20 27 34 41 48 55 62 69 76 83 90 97 104 111 118 125 132 139 146 153 160 167 varies varies 195 251 varies
Informed consent X
Medical release form X
GENERAL
Inclusion/exclusion checklist X X1
Locator form X X X X X X X X X X X
Demographics form X
PhenX Tier 1 additional (QLP, TUH) X
Motivations, attitudes & expectations form X
Treatment satisfaction survey X X
Relapse assessment X X X X X X X X X X X X X X X X X X X X X X
Continuing treatment forms X X X X X
Study termination form X X
SAFETY & MEDICAL
Medical & psychiatric history X
Physical exam, incl vitals X X3X
DSM-5 criteria X
CHRT-SR X X X X X X X X X X X X X X X X X X X
Clinical labs:   LFTs X X7X7X3X3X3X
Clinical labs:   HepB, HepC , HIV X
Urine pregnancy/birth control assessment X X2X2X2X3X3X3X3X3X3X
AEs & SAEs X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Injection site examination X3X3X3X3X3X3X
TREATMENT SCHEDULE
XR-NTX induction X
BUP-NX induction X
XR-NTX administration X approximately every 4 weeks with final injection occuring no later than week 22                     
BUP-NX dispensing X X X X X X X X X X X X
BUP-NX taper X4X4
Medical management X X X X X X X X X X X X X X X X
COMPLIANCE
BUP-NX dose log X X X X X X X X X X X X X X X X X X X X X X X X X X X4
Medical management log X X X X X X X X X X X X X X X X
Psychosocial log X X X X X X X X X X X X X X X X X X X X X X X X X
OUTCOME
Time Line Follow-Back X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Urine drug screen X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
ASI-Lite X X X X X
VAS craving opi[INVESTIGATOR_2438] X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
VAS non opi[INVESTIGATOR_2438], VNS X X X X X X X X X X X
HAM-D (Hamilton depression scale) X X X X X X X X X X X X X X
SOWS (subjective opi[INVESTIGATOR_9791]) X 3X 2X X X X X X X X X X X X X X
Fagerstrom X
Risk Assessment/HIV X X X X X X
Cognitive function (Trails, Stroop) X X X X X X
Detoxification utilization X
EQ-5D X X X X X X X X X X X
NMS X X X X X X X X X X X
Genetics sample X5X5X5X5X5
Family Origin X5X5X5X5X5
X1 = confirm just prior to randomization X4 = for those not able to transition to community-based BUP-NX treatment; may also occur if medication is discontinued in weeks 1-23
X2 = repeat only if more than seven days has elapsed since prior negative test X5= genetics sample and Family Origin questionnaire are only completed once, ideally  at screening, but may be collected at any visit requiring a blood draw
X3 = only after successful induction onto study medication, see 11.2.5 EOM6 = at the visit where medication ends complete EOM assessments and corresponding week research assessments; if relapse concurrent also complete EOT
X7 = Repeat if induction onto study medication occurs more than 2 weeks after randomization, see 11.2.5Active Treatment Follow upEarly end of 
Medication or 
Treatment (if not 
week 24)
33 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
11.1 General 
11.1.1 Inclusion/Exclusion  
This form lists each inclusion and exclusion criterion to document  eligibility. Eligibility is 
assessed continually as appropriate. Only participants who continue to meet study eligibility 
criteria are allowed to continue with the screening process, and randomization.  
11.1.[ADDRESS_9178] s the participant‚Äôs current address, email address, and phone 
numbers.  In order to facilitate locating participants if direct contact [CONTACT_9889], 
addresses and phone numbers of family/friends who may know how to reach the participant  are 
collected, as well as information such as social security number, driver‚Äôs license number and other information to aid in searches of public reco rds.  This information is collected at screening, 
and is updated at least every month during the active treatment phase, at the end- of-treatment 
visit ( EOT/ week 24), and at the week 28 and week 36 (or EOS) post-treatment follow -up visits. 
No information fr om this form is used in data analyses  nor is this information captured in the 
data capture system . 
11.1.[ADDRESS_9179] s information about demographic characteristics of the 
participant, including gender , date of birth, ethnicity , race, education, employment status , and 
marital status. This form is completed at screening.  
11.1.4 PhenX Tier 1  
The Substance Abuse and Addiction Collection of the PhenX Toolkit ( www.phenxtoolkit.org
) 
includes measures that are being adopted across NIDA -funded research. The Core Tier 1 
collection includes measures for demographics (age, ethnicity, gender, race, educational attainment, employment status, marital status), BMI, quality of life, and HIV risk and status; 
substance use measures include age of onset, past 30- day quantity and frequency, lifetime use 
for alcohol, tobacco and other substances.  Where possible, answers to Core Tier 1 questions 
are populated from the answers to questions from other assessments, but some additional 
questions may be incorporated to accommodate this requirement . Quality of Life (QLP) and 
Tobacco Use History (TUH) are [ADDRESS_9180] ations Form 
Motivation for participating in the study and attitudes  and expectations  regarding study 
medication are collected once at screening.  
11.1.6 Treatment Satisfaction Survey 
Satisfaction with treatment is recorded on the Treatment Satisfaction Survey completed at the 
end-of-treatment  visit ( EOT/ week 24).  
34 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
11.1.7 Relapse 
Relapse criteria is reviewed at each research visit beginning with visit 4 (since relapse by 
[CONTACT_9890] 21) and continuing through the end- of-treatment visit  
(EOT/ week 24 ). This form documents the time to event . 
11.1.8 Continuing Treatment Form s 
At the conclusion of study treatment, participants are discharged to treatment in the community. 
These forms document the treatment plan identified for the participant at week 24 or at the end 
of treatment  visit if treatment  is stopped early. At the 2 follow up visits  (weeks 28 and 36/EOS ), 
participants are asked whether they are adhering to the treatment plan, have initiated other 
treatment or discontinued all treatment.  
11.1.9 Study Termination  Form 
This form tracks the participant‚Äôs status in the study. It is completed at the week 36/EOS  visit or 
once the week [ADDRESS_9181] 
and present health conditions to help determine eligibility and to provide baseline information.  
This is  collected during s creening.  This information may be used in data analyses.  
11.2.2 Physical Examination  
The study clinician  completes a physical examination, including blood pressure and heart rate, 
to ensure that there are no medical concerns regarding participation and to gather  baseline 
information regarding the participant‚Äôs physical health.  During the screening physical exam, a 
description of the participant‚Äôs body habitus is documented and the study clinician examines the 
planned injection sites to ensure adequacy for XR -NTX gluteal intramuscular injection of 
naltrexone with the supplied needle.  The physical examination is performed at screening and is 
repeated at the end -of-medication visit (if medication is stopped early) or at the end- of-treatment 
visit (week 24).  The physical exam, blood pressure and/or heart rate may be repeated at MM 
visits at the discretion of the medical clinician.  
11.2.3 DSM-5 Criteria 
The DSM -5 criteria is  applied to determine a current diagnos is for substance use disorder .  This 
is completed at screening to determine eligibility.  
11.2.4 Concise Health Risk Tracking- Self Report (CHRT -SR) 
The CHRT -SR64 is a 16- item participant self -report assessment of suicidality and related 
thoughts and behaviors. The scale is designed to quickly and easily track suicidality in a manner consistent with the Columbia Classification Algorithm of Suicide Assessment (C -CASA).
65  The 
CHRT -SR is  assessed at screening, induction, at subsequent MM visits  and at the week 28 and 
35 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
36/EOS  visits . The CHRT -SR will assess high risk suicide ideation by a positive response 
(Agree or Strongly Agree) on any of the last three questions (thoughts of, thoughts of how 
and/or a specific plan to commit suicide) and prompt a clinician assessment for suicide risk 
before leaving the clinic.  
11.2.5 Clinical Laboratory Tests  
Liver function tests (LFTs , consisting of AST , ALT,  albumin and bilirubin)  and urine pregnancy 
test (for females) are performed to help determine eligibility at screening. Receipt and review of 
laboratory test results is necessary before confirming eligibility, conducting randomization and starting study medication.   Results of LFTs conducted within four weeks prior to randomization 
(e.g., collected as part of routine detoxification admission) are acceptable. For participants 
whose induction onto their assigned study medication is delayed for longer than 2 weeks  after 
randomization, LFTs  and urine pregnancy should be repeated prior to start of study medication.    
At screening, blood is collected for HIV antibody, hepatitis C virus (HCV) antibody and hepatitis 
B surface antigen (HBsAG)  and hepatitis B surface antibody (HBsAB)  tests . These tests do not 
determine eligibility and are only conducted on samples from participant s who are randomized.  
Results of HIV antibody, hepatitis C virus (HCV) antibody and hepatitis B surface antigen 
(HBsAG)  and hepatitis B surface antibody (HBsAB) tests conducted within four weeks prior to 
randomization (e.g., collected as part of routine detoxification admission) are acceptable.  
For participants whose induction onto their assigned study medication occurs within 2 weeks of Day 0, LFTs are repeated at  week 4, week 12, and at the end- of-medication visit (if medication 
is stopped early) or at the end- of-treatment visit (week 24). For participants whose induction 
onto their assigned study medication occurs more  than 2 weeks after day 0, LFTs are repeated 
approximately 4 and 12 weeks following induction (a +/ - [ADDRESS_9182]-induction LFTs 
is permitted), and at the end- of-medication visit (if medication is stopped early) or at the end- of-
treatment visit (week 24).   For participants who do not get inducted but continue on study, LFTs 
need not to be repeated at any of the planned visits with scheduled LFTs.  
A laboratory that is accredited by [CONTACT_9891] (CAP) or equivalent, and 
participates in the Clinical Laboratory Improvement Act of 1998 (CLIA) will perform these 
analyses.  The laboratory will provide normal values and proof of lab certifications.  
11.2.[ADDRESS_9183] feeding 
status . The pregnancy and birth control assessment, including on- site urine pregnancy tests , is 
conducted at screening  and may be repeated prior to randomization and/or induction.   Birth 
control assessment and urine pregnancy tests are repeated monthly and at the end- of-
medication visit (if medication is stopped early) or at the end- of-treatment visit (week 24).  
11.2.7 Adverse Events (AEs) and Serious Adverse Events (SAEs)  
At each medical management visit the study clinician  assesses  for AEs and SAEs b y asking the 
study participant, ‚ÄúHow have you been feeling since your last visit?‚Äù   AEs and SAEs may also 
be spontaneously reported to study staff at any visit following consent.   AEs and SAEs 
suggesting medical or psychiatric deterioration will be brought  to the attention of a study 
clinician  for further evaluation and management.   Medical management visits will emphasize 
overdose risk and risk -management; any reported overdose is recorded as an AE or SAE.  AE 
and SAE reporting is according to the reporting definitions and procedures outlined in the 
protocol and in accordance with applicable regulatory requirements.   
36 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
For the purpose of this study, the following AE s do not require reporting in the data system but 
is captured in the source documentation as medically indicated:  
‚Ä¢ Grade 1 (mild) unrelated adverse events  
This would typi[INVESTIGATOR_9792], cold, etc ., that were 
considered not reasonably associated with the use of the study drug/intervention.  
Events related to the injection of the study medication are recorded on the Injection Site 
Abnormality  (INA) form and will not be duplicate- reported on an AE form. Events related to 
withdrawal symptoms are captured on the SOWS and HAM -D and will not be duplicate -reported 
on an AE form.  Withdrawal symptoms not captured by [CONTACT_9892] -D should be reported 
as an AE. Events captured on study specific forms (INA, SOWS , HAM -D) are not  recorded 
separately as an AE, unless they meet the SAE definition. Any of these events that meet the 
definition of an SAE are reported on the AE/SAE form set . Any spontaneous reporting of 
withdrawal symptoms by [CONTACT_9893]: 
withdrawal symptoms reported at visits without sch eduled specific structured questionnaires 
(SOWS, HAM -D); and withdrawal symptoms not listed in the specific structured questionnaires 
(SOWS, HAM -D) reported at any visit . 
11.2.8 Injection Site Examination 
Appropriately qualified and trained medical personnel will  examine the injection site on the next 
Medical Management visit following the XR -NTX administration. Participants are asked to 
immediately report any injection site reactions to study staff for evaluation, monitoring, and 
possible referral, as needed. Injection site reactions should be documented on the Injection Site 
Abnormality Log.  
11.3 Compliance  
11.3.1 Dose Logs 
XR-NTX dosing is captured in the MM progress note and recorded in the appropriate CRF and 
dose log. A BUP- NX dose log document s the amount of medication dispensed for take -home 
dosing and reported as taken by [CONTACT_2299]. These forms are completed at relevant clinic 
visits through the end of the active treatment phase.  
11.3.2 Medical Management  
A Medical Management attendance log is completed to document attendance or non -
attendance at each Medical Management session during the active treatment phase.  The 
Medical Management discontinuation form is completed when MM visits end (at week [ADDRESS_9184]-
randomization, when the primary outcome of opi[INVESTIGATOR_9793], or for other reasons as determined by [CONTACT_1003] ). 
11.3.3 Psychosocial Participation  
At each weekly treatment visit, participants are asked to report on their participation in 
psychosocial TAU during the prior week.  
 
 
 
37 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
11.4 Drug Use and Psychological  
11.4.1 Timeline Follow -Back (TLFB)  
The Timeline Follow -Back66, 67 procedure is used to elicit the participant‚Äôs self -reported use of 
substances before and during the entire study period. At screening, this form is used to assess 
substance use reported by [CONTACT_9894] 30- day period prior to admission to detox . 
During detox, the TLFB is not captured in the data system until the date of discharge. The TLFB 
is administered at each study visit throughout the active treatment phase and through the end of 
the follow -up period to document the participant‚Äôs self -reported use of substances for each day 
since the previous TLFB assessment .  
11.4.2 Urine Drug Screen (UDS)  
Urine drug screens are collected at screening, as part of XR -NTX induction, weekly from week 1 
through week 24/EOT , and at follow -up visits at weeks 28 and 36/EOS .  In most cases the UDS 
should be completed before assessing self -reported drug use or dispensing medications .  All 
urine specimens are collected using FDA- approved one- step temperature -controlled urine drug 
test cups following all of the manufacturer's recommended procedures.  The UDS test s for the 
presence of the following drugs: opi[INVESTIGATOR_2438], oxycodone, barbiturates, benzodiazepi[INVESTIGATOR_1651], cocaine, 
amphetamine, methamphetamine, m arijuana, methadone, buprenorphine, and ecstasy 
(MDMA). In the event urine specimen tampering is suspected, either based on the observation or the adulterant tests, study staff should request a second urine sample and may observe the 
urine collection process according to clinic standard operating procedures.  A further validity 
check is performed using a commercially available adulterant test strip. 
11.4.3 Addiction Severity Index Lite (ASI -Lite) 
The ASI -Lite is derived from the Fifth Edition of the ASI
68, a structured clinical interview that 
yields scores for seven areas of functioning typi[INVESTIGATOR_9794], including medical 
status, employment status, drug use, alcohol use, family status, legal status, and psychiatric 
status. Opi[INVESTIGATOR_9795], including the main type of opi[INVESTIGATOR_9796], whether 
a prescription opi[INVESTIGATOR_9797], the onset of the use, the participant‚Äôs perception of the 
substance that is most problematic, and their present treatment goal will also be assessed at 
screening  as part of the ASI assessment. The ASI -Lite is completed at baseline, at  the end- of-
treatment  visit (week 24/EOT ), and at the week 36/EOS  follow -up visit.  
11.4.4 Visual Analog Scales (VAS)  
Participants‚Äô craving s for opi[INVESTIGATOR_2438], alcohol, and other drugs  are documented on visual analog 
scales (VAS) that range from 0 (no craving) to 100 (most intense craving possible).  These 
scales are completed for opi[INVESTIGATOR_9798], at the end-of-treatm ent visit (week 24/EOT ), and at each follow -up. 
They are completed for alcohol, stimulants and tobacco craving at screening, weeks 4, 8, 12, 
16, 20, 24 /EOT , 28, and 36/EOS .  VAS also document s responses to opi[INVESTIGATOR_2441], in the event 
that participant s use opi[INVESTIGATOR_9799].  
11.4.5 The Hamilton Depression Scale (17 item) (HAM -D) 
The 17- item Hamilton Depression Scale ( HAM-D) is a clinician -administered instrument, useful 
for following both depression and suicidal ideation, and also for following typi[INVESTIGATOR_9800] (e.g., low appetite, fatigue, poor sleep). For the purpose of this study, 
adequately trained research staff conduct the Hamilton Depression Scale (HAM -D).   
38 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
The HAM-D is completed at screening, at weeks 1, 2, 3, 4, 8, 12, 16 and 20, at the end- of-
treatment visit ( week 24/EOT ), and at each follow- up. A score of 1 or more to item 3 (suicidality) 
prompt s a clinician assessment for suicide risk before leaving the clinic.  
11.4.6 The Subjective Opi[INVESTIGATOR_9721] (SOWS)  
This scale is usef ul for following self -reported opi[INVESTIGATOR_9801].  It is administered at  
baseline, induction, weekly during the first month after randomization, and at weeks 8, 12, 16, 
and 20, at the end of treatment (EOT/ week 24), and at each follow -up.  At the induction visit for 
the XR -NTX group the SOWS is administered three times, the first time within the hour prior to 
the naloxone challenge, the second time 10- [ADDRESS_9185] for Nicotine Dependence (FTND)  
The Fagerstr√∂m Test for Nicotine Dependence (FTND) is used for assessing nicoti ne 
dependence 69, 70 and is administered at baseline. 
11.4.8 Risk Assessment Battery (RAB)  
The Risk Assessment Battery (RAB)71 is a self -administered assessment of engagement in 
activities that increase the likelihood of contracting HIV. Several scores that measure drug risk, 
sex risk, and total risk are computed. This measure is completed at baseline, at week 12, and at 
the end -of-treatment visit (week 24/EOT ), and at the week 36/EOS  follow -up visit.  
11.4.9 Cognitive Function Tests  
Cognitive function is assessed using simple, brief, pen and paper tests  (Trail Making Test, Parts 
A and B, and Stroop).  These tests  are complete d at baseline, week 4, 8, 16, and at the end-of-
treatment visit ( EOT/ week 24).  
11.4.10 Detoxification Utilization Form 
Data on detoxification, including number of days on the unit and medications received, is 
collected.  
11.4.11 EuroQol  (EQ-5D)  
The EuroQ ol instrument is a standardized generalized (non disease- specific) system for 
describing and valuing health- related quality of life. The instrument consists of two components; 
the Eur oQol classification instrument, which describes the respondent‚Äôs health within [ADDRESS_9186] Quality- Adjusted Life 
Year estimates (QALYs). The EuroQ ol instrument is the recommended Health Quality Index for 
Economic Evaluations in the  Substance Abuse and Addiction Collection of the PhenX Toolkit 
(www.phenxtoolkit.org ). The EQ -5D is  completed at baseline, week 4, 8, 12, 16, 20, and 24, at 
the 2 follow up visits, at the EOT visit if treatment ends early and at the EOS visit if not done at 
week 36. 
11.4.12 Non-Study Medical and Other Services (NMS)  
Medical services that are not part of the treatment intervention are recorded on the NMS form. 
The NMS form captures services received outside the study and CTP including therapy visits, 
39 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9187] with the criminal justice 
system. Validity of self -reported health care utilization has been demonstrated.72-74  The NMS is 
completed at baseline, week 4, 8, 12, 16, 20, and 24, at the 2 follow up visits, at the EOT visit if 
treatment ends early and at the EOS visit if not  done at week 36. 
11.5 Genetics Protocol Measures 
Genetics protocol measures include one- time blood sample collection and completion of a 
Family Origin questionnaire. The blood sample should be collected at screening, but may be 
collected at any visit where there is a scheduled blood draw.  The Family Origin questionnaire 
can be completed at any visit, ideally at the same time as the blood draw.  
The Family Origin form is designed to be interviewer administered.   It collects information about 
the participant and her/his biological family members‚Äô race/ethnicity, place of birth, and ancestry.  If a participant does not know the information requested, the participant may answer ‚Äúunknown‚Äù.  
40 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
12.0 STATISTICAL ANALYSIS  
12.1 General Design 
The primary goal of the study is to estimate the difference, if one exists, between XR -NTX and 
BUP-NX in the distribution of the time to relapse (i .e., loss of persistent abstinence) during the 
6-month trial.  
12.1.1 Primary and Secondary Outcomes (Endpoints)  
Primary Endpoint :  The primary outcome measure is the time to the event with the event called 
relapse. By [CONTACT_9857]. Relapse occurs if 
the participant is using any non- protocol prescribed opi[INVESTIGATOR_9754] [ADDRESS_9188] -
randomization or thereafter.  Operationally, loss of persistent abstinence is defined as either: (a) 
four consecutive opi[INVESTIGATOR_9755], or (b) seven consecutive days of use by [CONTACT_6270] -report.   A use 
week is defined as any week during which a participant self-reports at least one day of use 
during that week, provides a urine sample positive for non- protocol opi[INVESTIGATOR_2438], or fails to provide a 
urine sample.   Self-report of opi[INVESTIGATOR_2480] (heroin or prescription opi[INVESTIGATOR_2438]) and other substance use is 
ascertained at each weekly study visit using the Timel ine Follow -Back for each day leading back 
to the previous visit.   Urine is  collected at each study visit and tested for opi[INVESTIGATOR_2438].   In the event 
that a participant reports no use, but their urine test indicates use, then the week is considered a 
use week.   Missing urine samples are classified as positive. The time of the event occurs at the 
start of the qualifying clinical event period (e.g., first of the 7 consecutive use days or start of the 
4 consecutive weeks of use).  
Secondary Endpoints: Secondary endpoints include success of treatment initiation and selected 
opi[INVESTIGATOR_9802] 9.2.  A set of additional secondary 
endpoints that describe adverse experiences and clinical states are detailed in that section.   
12.1.2 Design 
The therapeutic strategies defined above are evaluated and compared in a two- arm randomized 
open- label multi -center trial.  
12.2 Rationale for Sample Size and Statistical Power  
Original Projected Sample Size:  200 per treatment group.  N = 400 total.  
Data Analysis Modification Projected Sample Size: ~300 per treatment group. (N~600 total  
sufficient to enroll 350 late randomizers ). 
Rationale: The primary outcome is the time to relapse as defined above. Meta- analyses of 
randomized controlled trials of BUP -NX maintenance treatment for opi[INVESTIGATOR_9803] 50% of patients are retained i n BUP -NX treatment with good clinical outcome 
over [ADDRESS_9189] had few prior randomized 
comparisons but observations from a recent Russia- based trial evaluating the XR -NTX dose 
and formulation proposed for this trial had good results with 53% receiving all monthly injections 
and retained for [ADDRESS_9190] a 6- month success rate of 40% 
with exponential failure.  We use a lower success target than indicated in the above paragraph 
because the use of the early randomization time point is expected to increase the percentage of 
41 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9191] on detectable alternatives if a 
higher 50% success rate was used.  From the plot below, we observe that the 95% CI width for the hazard ratio for the 50
th percentile of the simulation results under both the null and 
alternative hypotheses decreases by 31%, 19%, and 14%  as the sample size increase by 
50/arm from a base of 50/arm.  CI width decreases by 11% when the sample size increases 
from 200/arm to 250/arm.  We have selected 200/arm as subsequent precision improvements 
with this criteria are close to  10% per 100 sampling units.  
 Beyond a sample size of 150 to 200 patients per group, further increments in sample size (200 
per group, 250 per group, 300 per group, etc .) yield diminishing returns in terms of only 
relatively small further narrowing of the 95% confidence interval.  The rationale for increasing 
the total sample size to N ~600, in the event of a significant difference in induction success rate 
among early randomizers, is that given the current ratio of early to late randomizers, N ~600 
total will yield approximately 250 early randomizers and 350 later randomizers.  350 late 
randomizers (N = 175 per treatment group) is close to the 400 (N = 200 per group) originally planned, and will yield a very similar (only slightly wider) 95% confidence interval.  This will 
preserve the intent to achieve a relatively precise estimate of the difference in relapse rates 
among late randomizers.  
 
Simulation results for the 50th and Upper 95th percentile of the 95% Confidence Interval 
Widths for the Hazard Ratio, selected sample sizes with lambda=0 and lambda=0. 678 
 
The decision theoretic properties of n= 200/arm is evaluated further under a decision theoretic 
approach and using the logrank test.  With two -sided alpha = 0.05, N = 400 total participants 1.665 
0.998 
0.767 
0.637 
0.554 
0.496 0.455 1.210 
0.726 
0.556 
0.461 
0.403 0.358 0.329 1.057 
0.731 
0.593 
0.512 
0.455 0.416 0.386 0.769 
0.529 
0.429 
0.371 0.329 0.301 0.279 
[IP_ADDRESS].[IP_ADDRESS].41.61.[ADDRESS_9192] under Alternative
42 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
provides 90% power to detect a hazard ratio of . 63 for the second treatment.  Table 4 provides 
additional characterization of power  characteristics of the sample size.  
 
Table 4.   Detectable Alternatives and Power for 2- tailed 5% level logrank test without 
censoring Null distribution has a 40% 6 month success rate, N1=N2=200 
Power (%)  Hazard Ratio 6 Month Survival Rate (%)  
under the Alternative  
90.[ADDRESS_9193] 79% power to detect, using a 2 -tailed 5% level test of a binary endpoint, a [ADDRESS_9194] in its ability to determine whether there are important differences in therapeutic 
success rates for major demographic or baseline clinical factors.  
12.2.1 Projected Number of Sites, and Participants per Site  
Number of Sites: We are targeting participation by 8 sites.  Eligible sites will be programs that 
admit large numbers of actively using opi[INVESTIGATOR_2480]- dependent patients per year to inpatient/residential 
treatment  or partner with such detox facilities , where, presently, usual treatment consists of 
detoxification, followed by [CONTACT_9895] ‚Äúdrug free‚Äù counseling of some type, and few 
patients have access to medication (methadone, buprenorphine, or naltrexone) after discharge. This wo uld support at least four randomizations per  site per  month, or up to  100 randomizations 
per site over the up to 24-month enrollment period.  
Participants per Site: We expect [ADDRESS_9195] the medications under real world conditions.  It was also anticipated that induction onto BUP -NX would be easier than induction 
onto XR -NTX for patients who are randomized ‚Äúearly‚Äù while opi[INVESTIGATOR_9804].  This 
is because BUP- NX can be safely initiated while opi[INVESTIGATOR_9805], as long as some 
signs of withdrawal begin to develop, while for XR -NTX one needs to wait until detoxification is 
completed and this delay  is an opportunity for attrition.  The concern is that a higher induction 
failure rate on XR -NTX, among those randomized early  will contribute to differences in outcome 
(time -to-relapse) across the 6 month trial, with induction failure leading to relapse.  If this is the 
case, then the interaction between early vs . late randomization and treatment assignment on 
the primary outcome (time to relapse) becomes germane. 
43 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
Therefore, after the entry of 100 ‚Äúearly randomizers‚Äù (as defined in Section 8.3) we will com pare 
the induction success rate in these early randomizers on XR-NTX vs . BUP-NX with a test of 
difference between proportions.  The decision rule has >80% power (alpha=2.5% 1 tail) to 
identify differences of .25 or greater if the true initiation rate for the BUP -NX is in the expected 
range (>=.85).  If the difference in induction failure rate is significant, then: 
1. Increase the sample size to end enrollment at such time as [ADDRESS_9196] 
been enrolled to increase power to estimate the difference in primary outcome (time- to-
relapse) in this late randomizer group.  It is projected that at such time the total N will be approximately 600.  
 
2. Amend the data analysis plan (Section 12.4 of the protocol) . 
 
12.4 Statistical Methods for Primary and Secondary Outcomes 
Primary Outcome Analysis : 
The initial analysis will be the construction of the asymptotic 95% CI for the hazard ratio of the 
difference between the treatment arms in the time to event distribution for the primary outcome. 
The study arm success rates with confidence intervals at week 24 and the difference in success 
rate at that time point and associated confidence intervals will be constructed.  
If the data analysis modification is implemented, the binary baseline variable (early vs . later 
randomization as previously defined) is included in the primary outcome analysis (outcome = 
time-to-relapse) as a covariate, a priori.  The early vs . late randomization covariate by [CONTACT_9896].  If the covariate (early vs . late 
randomization) by [CONTACT_9897] P < .10, then the interaction term is retained in the final model.  To characterize the interaction, the effect of treatment assignment 
(i.e., the difference in time- to-relapse between treatments) is estimated separately in early vs . 
late randomizers, and these two separate estimates become the primary findings of the study.  Induction success rate is a secondary outcome measure.   
Subsequent analyses will explore the treatment effect as a function of time, stratification 
variables and other factors that may have differential impact on treatment success. The 
analyses will first model the time to event primary outcome measure as a function of treatment 
assignment (XR -NTX vs. BUP -NX), opi [INVESTIGATOR_9806] a 
proportional hazards regression model.  The constancy of the relative hazard assumption will be examined via the interaction of treatment and time, and the interaction between treatment and 
baseline severity will be tested.   
If the stratum by [CONTACT_9898] a p- value<0.10, then this will be taken to indicate 
differences in strata -specific efficacy. We note that if this interaction is qualitative (i.e., reversal 
of treatment advantage in the subgroups
75) this will have important consequences for future 
treatment and research decisions.  We will test the pair -wise differences between XR -NTX and 
BUP-NX, separately in the low dependence vs. high dependence subgroups, and further 
examine the differences with an ordinal/continuous dependence covariate.   Note that we are not 
powering the study to detect the interaction; however, given the likelihood that baseline predicts outcome, or may interact with treatment
 76, 77, we are acknowledging that the coefficient of the 
main effect of treatment in the model is not meaningful in the presence of an interaction with baseline covariates, and that a significant interaction should prompt testing of the region(s) of 
the baseline covariate where the probability of treatment successes differ.
77, 78  
44 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
Secondary analyses of the 24 week successes will include screening baseline variables to 
identify potential subgroups in the XR- NTX group with differential results.   
Secondary Outcome Analyses : 
Successful initiation of protocol therapy is an important binary outcome that may also be useful to subsequently explain differences in the primary outcome. Most other secondary outcome 
analyses will follow a similar form and strategy to that above, with different linear models as 
appropriate for the form of the secondary outcome variable: dichotomous secondary outcomes will use logistic regression; time -to-event variables will use survival analysis with Cox models; 
continuous variables or count variables (e.g., bags per day of heroin use) will use mixed effect models depending on the distribution of the outcome (e.g., normal, Poisson, negative binomial, 
zero-inflated).  Repeated measures will have time in the model in addition to treatment and 
baseline variates.  
12.5 Significance Testing 
The primary analysis focuses on estimation of the treatment difference and uses a criterion with 
2.5% of the normal distribution mass in each tail. Levels of significance for additional tests and 
analyses are as identified.  
12.6 Exploratory Analyses 
Analysis of Predictors and Moderators of Treatment Effects : 
Exploratory analyses will mainly involve exploring baseline demographic and clinical variables, 
and candidate genetic markers, as predictors of success, or as moderators of differences in 
success between XR- NTX and BUP -NX.  This can be analyzed by [CONTACT_9899] a 
covariate in the models outlined above for primary or secondary outcome measures, and testing for the main effect of the covariate, and covariate by [CONTACT_9900].  Alternatively, 
demographic, clinical, and genetic factors could be examined as predictors of outcome separately within the XR- NTX and BUP -NX groups.  
Analysis of Mediators of Treatment Effects : 
Some during -treatment variables will also be of interest to explore as potential mediators of 
outcome.  For example, opi[INVESTIGATOR_9807], mainly use after discontinuing naltrexone (‚Äúunblocked use‚Äù), but also repeated epi[INVESTIGATOR_9808] (‚Äúblocked use‚Äù).
61, [ADDRESS_9197] better understanding of personalized therapeutic strategies by [CONTACT_9901].   
45 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9198] assumptions (missing at random) may not be plausible.  
Other outcome variables (opi[INVESTIGATOR_9809], craving, mood, etc.) will have missing data due to missed visits and dropout from treatment and from study participation. 
The generalized linear model, or mixed effects model frameworks that will be used for analyses, 
works with what data are gathered, and assumes missing data are missing at random.  For selected secondary outcome analyses, sensitivity analyses will be considered to examine the 
stability of estimated treatment effects in the face of departures fr om the assumption of missing 
at random.  
Aggressive tracking procedures are put into effect to attempt to locate participants and re-
engage them, and to minimize missing data.  These procedures are detailed in the study  MOP .  
The greatest likelihood of violation of the assumption of missing at random derives from dropouts, since participants assigned to XR -NTX may dropout from the study for different 
reasons than participants assigned to BUP -NX, creating the potential for differential attrition.  
Differentia l study attrition, where outcome differs between the dropouts from the assigned 
treatments is a threat to the validity of the outcome analysis.  Minimizing the rate of study dropout and loss to follow -up, through aggressive tracking and follow -up, serves to reduce this 
threat.  At a minimum the data gathered on dropouts can be used to test the assumption of 
missing at random, by [CONTACT_9902].  
12.9 Demographic and Baseline Characteristics  
Demographic variables : 
Gender, age, race , ethnicity, educational level, employment status, marital status . 
Baseline clinical characteristics : 
Opi[INVESTIGATOR_9810], severity of other substance use, severity of mood/anxiety 
symptoms, seve rity of opi[INVESTIGATOR_9801], current/past co- occurring psychiatric 
disorders, current medical disorders, select genetic markers (e.g., candidates will include the 
A118G variant of the mu- opi[INVESTIGATOR_9811], the G36T variant of the kappa opi[INVESTIGATOR_9812], and the 3‚ÄôUTR haplotype of the prodynorphine gene), history of legal problems, currently 
under legal supervision (parole, probation, or mandated).  
Baseline demographic and clinical variables will be summarized for each arm of the study. Descrip tive summaries of the distribution of continuous baseline variables will be presented with 
percentiles (median, 25th and 75th percentiles), and with mean and standard deviation. 
Categorical variables will be summarized in terms of frequencies and percentages. Since 
randomization is expected to produce balance at baseline between the two arms of the trial, 
statistical comparisons of treatment groups with respect to baseline characteristics should be 
more informal.  The updated CONSORT statement
80 no longer recommends formal testing of 
statistical significance of differences between baseline characteristics.   
 
46 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
12.10  Safety Analysis  
Adverse events (AEs), including serious adverse events (SAEs), will be summarized by [CONTACT_9903] (The Medical Dictionary for Regulatory Activities). 
Adverse events will be presented in two ways: (1) the number and proportion of participants 
experiencing at least one incidence of each event will be presented overall and by [CONTACT_6490]; and (2 ) a table displaying the total number of each event will be given overall and by 
[CONTACT_1570]. Listings of serious adverse events will be given, sorted by [CONTACT_3148], body 
system, and preferred term. Detail in these listings will include severity, relati onship to study 
drug, and action taken as available. Treatment arm differences will be monitored by [CONTACT_4318].  
47 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
13.0 REGULATORY COMPLIANCE AND SAFETY MONITORING  
13.1 Statement of Compliance 
This trial will be conducted in compliance with the current version of the protocol, current Good 
Clinical Practice (GCP), the principles of the Declaration of Helsinki, and all other applicable 
regulatory requirements. Participating sites must obtain written approval of the study protoc ol, 
consent form, other supporting documents, and any advertising for participant recruitment from their local institutional review board (IRB) in order to participate in the study. Prior to study initiation, the protocol and the informed consent documents will be reviewed and approved by 
[CONTACT_9904] (ERC) or IRB. Any amendments to the protocol or 
consent materials must be approved before they are implemented. Annual progress reports and 
local Serious Adverse Event (SAE) reports will be submitted to each IRB, according to its usual 
procedures.  
13.[ADDRESS_9199] the study at their respective site. Should changes to the study protocol become necessary, protocol 
amendments will be submitted in writing by [CONTACT_9905]. In addition, IRBs will approve all consent forms, recruitment materials, social 
media use and any materials given to the participant. Annual reports and progress reports will be submitted to the IRBs annually or at a frequency requested by [CONTACT_9906]. Each site investigator is responsible for maintaining in his/her research files copi[INVESTIGATOR_9813](s), IRB -approved consent document(s), including approval for all protocol 
modifications pertinent to his/her performance site(s). These materials must be received by [CONTACT_9907] a given site, and must be available 
at any time for audit.  
13.3 Research Advisory Panel of [LOCATION_004] ([LOCATION_004] sites only)  
Prior to initiating the study, the sponsor will obtain written approval from the Research Advisory Panel of [LOCATION_004] (RAP- C). Any planned research project to be conducted in [LOCATION_004] 
requiring the use of a Schedule I or Schedule II Controlled Substance as its main study drug as well as research for the treatment of controlled substance addiction or abuse utilizing any drug, scheduled or not (SAT) must be submitted to RAP -C for review and approval prior to study start -
up. Study approval is based on review of the study protocol, consent form, and other pertinent study documents.  Yearly reports will be provided to the RAP -C in order to obtain continuing 
study approval.  
13.4 Confidentiality  
By [CONTACT_9908], Ethical Review Committee, or similar expert committee; affiliated institution; and 
employees only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. The Study lead investigator has obtained a 
federal Certificate of Confidentiality (CoC), protecting participants against disclosure of sensitive inform ation (e.g., drug use), and will distribute it to all sites when received. The NIH office that 
issues the CoC will be advised of changes in the CoC application information. Participating CTP 
sites will be notified if CoC revision is necessary.   Confidentia lity will be maintained in 
48 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
accordance with all applicable federal regulations and/or state/Commonwealth law and 
regulations.  
Participant records will be kept confidential by [CONTACT_9909], secure separate storage of any documents that have participant identifiers, and 
secure computing procedures for entering and transferring electronic data.  
13.4.[ADDRESS_9200] (HIPAA)  
Study sites may be required by [CONTACT_9910].   Releases of participant identifying information that are 
permitted by [CONTACT_9911], but which are prohibited by [CONTACT_9912]/or state/Commonwealth law and regulation, are prohibited.  Sites will be 
responsible for communicating with their IRBs or Privacy Boards and obtaining the appropriate approvals or waivers to be in regulatory compliance.  
13.4.2 Investigator Assurances 
Each institution‚Äôs IRB of record reviewing the study at the community treatment program (CTP) must file (or have previously filed) a Federal Wide Assurance (FWA) with the DHHS Office for 
Human Research Protection setting forth the commitment of the organization to establish 
appropriate policies and procedures for the protection of human research subjects, with 
documentation sent to NIDA or its designee. Research covered by [CONTACT_9913]‚Äôs receipt of certification that the research has been reviewed and approved by [CONTACT_9914] (45 CFR 46.103(b) and (f)). 
Prior to initiating the study, the principal investigator [INVESTIGATOR_9814] -investigators at each study site will 
sign a protocol signature [CONTACT_3264], providing assurances that the study w ill be performe d according 
to the standards stipulated therein. 
13.4.[ADDRESS_9201] a DEA 
registration (facility research registration or a practitioner registration) that has the address 
where study drug will be shipped on the registration. Additionally, dispensing any controlled 
substance requires a DEA registration unless exempt by [CONTACT_9915] 1301.22- 1301.26.  
13.5.[ADDRESS_9202] a diverse study population. If 
49 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
difficulty is encountered in recruiting an adequate number of women and/or minorities, the 
difficulties involved in recruitment will be discussed in national conference calls and/or face- to-
face meetings, encouraging such strategies as linkages with medical sites and or treatment 
programs that serve a large number of women or minorities, advertising in newspapers or radio 
stations with a high female or minority readership/listening audience, etc.  
13.5.3 IND Requirements  
Medications to be used in this study will be used in accordance with their approved labeling and 
therefore there is no plan to submit an IND application.  
13.5.4 Regulatory Files  
The regulatory files should contain all required regulatory documents, study -specific documents, 
and all important communications. Regulatory files will be available at each partic ipating site for 
regulatory document inspection for compliance prior to study initiation, throughout the study, as well as at study closure.  
13.5.5 Records Retention and Requirements  
Research records for all study participants (e.g., case report forms, source documents, signed 
consent forms, and regulatory files) are to be maintained by [CONTACT_9916] a secure location 
for a minimum of [ADDRESS_9203] be 
received by [CONTACT_9917].  
13.5.6 Audits 
The Sponsor has an obligation to ensure that this trial is conducted according to good research 
practice guidelines and may perform quality assurance audits for protocol compliance. The Lead 
Investigator and authorized staff from the National Lead Study Team; the National Institute on Drug Abuse Clinical Trials Network (NIDA CTN, the study sponsor); NIDA‚Äôs contracted agents, 
monitors or auditors; and other agencies such as the Department of Health and Human Services (DHHS), the Office for Human Research Protection (OHRP) and the site‚Äô s Institutional 
Review Board may inspect research records for verification of data, compliance with federal guidelines on human participant research, and to assess participant safety.  
13.5.[ADDRESS_9204] or outcome of the trial or increase risk to study participants. 
Adverse Event reporting and Serious Adverse Event reporting will occur as described in Appendix A. At the completion of the trial, the national lead Investigator will provide a final report 
to the Sponsor.  
13.5.8 Informed Consent  
All potential candidates for the study will be given a current local IRB -approved copy of the 
Informed Consent Form to read. Appropriately qualified and trained study personnel will explain all aspects of the study in lay language and answer all of the study candidate‚Äôs questions. 
Participants who remain interested after receiving an explanation of the study will be given a 
informed consent quiz to test his/her understanding of the project, the purpose and procedures 
50 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
involved, and the voluntary nature of his/her participation. Those who cannot successfull y 
answer quiz items will have the study re- explained by [CONTACT_9872] a focus on aspects 
they did not understand.  Anyone who cannot demonstrate appropriate understanding of the 
study will be ineligible to participate and will be assisted in finding other treatment resources. 
Those who demonstrate understanding of the study and voluntarily agree to participate will be asked to sign the informed consent form. Participants will not be administered any assessments 
or study procedures prior to signing informed consent.  
The informed consent process is a means of providing study information to each prospective 
participant and allows for an informed decision about participation in the study. The informed 
consent form must be updated or revised whenever important new safety information is 
available, or whenever the protocol is amended in a way that may affect a study participant‚Äôs 
participation in the trial. Each study site must have the study informed consent approved by [CONTACT_9918](s). The site must maintain the original signed informed consent for every participant in 
a locked, secure location that is in compliance with their local IRB and institutional policies and 
that is accessible for quality assurance review and regulatory compliance. Every study 
participant should be given a copy of the signed consent form to keep for reference. Individuals 
who refuse to participate or who withdraw from the study will be treated without prejudice. 
13.5.9 Clinical Monitoring  
The monitoring of the study site will be conducted on a regular basis using a combination of NIDA -contracted monitors and RRTC (Regional Research and Training Center) site managers. 
Investigators will host periodic visits by [CONTACT_9919]. The purpose of these visits is to encourage and assess compliance with GCP requirements and to 
document the integrity of the trial progress.  
NIDA contract monitors will monitor study compliance and study procedures to assess 
compliance with the protocol, GCP, and applicable regulations.  NIDA contract monitors will 
assess accurate submission of  data and that data are in agreement with source documentation 
and will also review regulatory/essential documents such as correspondence with the IRB. Areas of particular concern will be participant informed consent, protocol adherence, safety 
monitoring, IRB reviews and approvals, regulatory documents, participant records, study drug accountability, and principal investigator [INVESTIGATOR_9815]. Reports will be 
prepared follow ing the visit and forwarded to the site principal investigator, the lead investigator 
and NIDA.  
Qualified RRTC site managers will provide site management for each site during the trial.  This 
will take place as specified by [CONTACT_9920], RRTC  PI [INVESTIGATOR_9816], detect, and correct problems at the study sites.  RRTC  staff will 
ensure site staff is trained and able to conduct the protocol appropriately and that study 
procedures are properly followed.  If the RRTC staff‚Äôs review of study documentation indicates 
that additional training of study personnel is needed, RRTC staff will undertake or arrange for 
that training.  Details of the contract monitoring, RRTC site management, and data monitoring 
are found in the study Q uality Assurance M onitoring plan.  
13.5.10 Study Documentation  
Study documentation includes all case report forms, workbooks, source documents, monitoring 
logs and appointment schedules, sponsor -investigator correspondence, and signed protocol 
and amendments, Ethics Review Committee or Institutional Review Committee correspondence and approved current and previous consent forms and signed participant consent forms.  
51 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9205], that will be considered the 
source.  
13.6 Safety Monitoring  
13.6.1 Medical Monitor  
A NIDA -assigned Medical /Safety Monitor will be responsible for overseeing safety and for 
evaluating all Adverse Events (AEs). He/She will review all Serious Adverse Ev ents (SAEs) 
within five days of their occurrence and all other Adverse Events on a regular basis.  It is the responsibility of the site principal investigator [INVESTIGATOR_9817].  It is also the site principal investigators‚Äô responsibility to inform the IRBs per local IRB guidelines.  
13.6.[ADDRESS_9206] (DSMB)  
This study will utilize the CTN DSMB to oversee ongoing trial progress. The purpose of this 
board is to determine whether risks emerge during the conduct of the trial that make 
continuation unethical (e.g., clear and significant superiority of one condition over another).  This 
process is intended to assure the IRBs, the sponsor, and investigators that participants are 
provided with an accurate and ongoing risk evaluation when participating in CTN research trials.  Safety monitoring begins with the initial review of the protocol during the study development 
process .  The DSMB will meet at least annually.  Recommendations from these reviews will be 
distributed to the site lead investigator for submission to their IRB.  
13.6.3 Protocol Deviations  Reporting and Management  
Any departure from procedures and requirements outlined in the protocol will be classified as 
either a major or minor protocol deviation.  The difference between a major and minor protocol 
deviation has to do with the seriousness of the event and the corrective action required.  A 
minor protocol deviation is considered an action (or inaction) that by [CONTACT_9921], rights, or welfare of a 
study participant.  Major protocol deviations are departures that may compromise the participant safety, participant rights, inclusion/exclusion criteria or the integrity of study data and could be 
cause for corrective actions if not rectified or prevented from re- occurrence.  Sites will be 
responsible for developi[INVESTIGATOR_9818].  Those corrective action plans  may be reviewed/approved by [CONTACT_9922]‚Äôs IRB.  All protocol deviations will be monitored at 
each site for (1) significance, (2) frequency, and (3) impact on the study objectives, to ensure 
that site perform ance does not compromise the integrity of the trial.   
 Sites will encourage all participants to attend visits in person, however visits by [CONTACT_9923]. In those cases, research staff should complete as many of the study procedures and assessments as possible. Missed assessments will be noted as a protocol deviation.  The 
research team should also note that missed urine drug screens associated with phone visits will contribute towards meeting relapse criteria. 
 
52 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
All protocol deviations will be recorded in the Electronic Data Capture (EDC) system via the 
Protocol Deviation CRF. The CCC, DSC and the Lead Investigator must be contact[CONTACT_9924].  
 Additionally, each site is responsible for reviewing their local IRB‚Äôs definition of a protocol 
deviation or violation and understanding which events need to be reported. Sites must 
recognize that the CTN and IRB definition of a reportable event may differ and act accordingly in following all reporting requirements for both entities. 
13.6.4 Adverse Events (AEs)  
The Lead Investigator (LI) may appoint a Study Clinician ( e.g., MD, DO, PA, NP, or RN ) for this 
study, who will review or provide consultation for each serious adverse event as needed.  These  
reviews will include an assessment of the severity and causal  relationship with the study drug or 
study procedures.  The Study Clinician  will also provide advice for decisions to exclude, refer, or 
withdraw participants as required. In addition, NIDA will  assign a Medical Monitor to this protocol 
to independently review the safety data, and present it to the DSMB for periodic review.  The 
medical monitor will determine which adverse events require expedited reporting to NIDA, the 
DSMB, pharmaceutical/distributors (Reckitt Benckiser Pharmaceuticals , Inc.) and regulatory 
authorities.  This will include all suspected adverse reactions that are serious and unexpected.  
The study staff will be trained to monitor for and report adverse events and including seriou s 
adverse events.  
Each of the participating CTPs has established practices for managing medical and psychiatric 
emergencies, and the study staff will continue to utilize these procedures.  Study medical 
clinicians at each CTP will be responsible for monitoring participants for possible clinical 
deterioration or other problems, and for implementing appropriate courses of action.  
 
Standard definitions for adverse events and serious adverse events, their identification, 
characterization regarding severity and relationship to therapy and processing are described in 
Appendix A.  
For the purpose of this study, the following AE will not require reporting in the data system but 
will be captured in the source documentation as medically indicated:  
‚Ä¢ Grade 1 (mild) unrelated adverse events  
This would typi[INVESTIGATOR_9792], cold, etc ., that were 
considered not reasonably associated with the use of the study drug/intervention.  
Events related to the injection of the study medication will be recorded on the Injection Site 
Abnormality  (INA) form and will not be duplicate- reported on an AE form.  Events related to 
withdrawal symptoms will be captured on the SOWS and HAM -D and will not be duplicate-
reported on an AE form.  Withdrawal symptoms not  captured by [CONTACT_9925] -D should be 
reported as an AE. Events captured on study specific forms (INA, SOWS, HAM -D) will not be 
recorded separately as an AE, unless they meet the SAE definition. Any of these events that meet the definition of an SAE will be reported on the AE/SAE form set . Any spontaneous 
reporting of withdrawal symptoms by [CONTACT_9926]: withdrawal symptoms reported at  visits without scheduled specific structured 
questionnaires ( SOWS, HAM -D); and withdrawal symptoms not listed in the specific structured 
questionnaires (SOWS, HAM -D) reported at any visit . 
53 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
13.6.5 Serious Adverse Events 
For the purpose of this study, the following  events will not be reported as an SAE. D etox 
admissions will  be recorded on study specific forms  in the data system .  They would be reported 
to local IRBs per local IRB guidelines:  
‚Ä¢ Aspects of the index detox admission will be documented on the Detox Utilization Form 
while o ther detox admissions will be documented on the NMS form  
‚Ä¢ Admission for labor and delivery  
‚Ä¢ Admission for elective or pre -planned surgery  
13.6.6 Known Potential Toxicities of Study Drug/Intervention 
Refer to the package inserts for XR -NTX and BUP -NX in Appendices C and D. 
54 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
14.0 DATA MANAGEMENT AND PROCEDURES  
14.1 Design and Development  
This protocol utilize s a centralized Data and Statistics Center (DSC).  The DSC is responsible 
for the development of the electronic case report forms (eCRFs), development and validation of 
the clinical study database, ensuring data integrity, and training site and participating RRTC  
staff on applicable data management procedures.  AdvantageEDC, a web- based distributed 
data entry system, has been implemented.  This system has been developed to ensure that 
guidelines and regulations surrounding the use of computerized systems used in clinical trials 
are upheld.  The remainder of this section provides an overview of the data management plan 
associated with this protocol.  
14.2 Site Responsibilities  
The data management responsibilities of each individual CTP is specified by [CONTACT_9927]‚Äôs Guide.  
14.3 Data Center Responsibilities  
The DSC 1) develops a data management plan and conduct s data management activities in 
accordance with that plan, 2) provides final guided source documents and eCRFs for the 
collection of all data required by [CONTACT_1758], 3) develops data dictionaries for each eCRF that 
comprehensively define each data element, 4) conduct s ongoing data monitoring activities on 
study data from all participating CTPs, 5) monitor s any preliminary analysis data cleaning 
activities as needed, and 6) rigorously monitor s final study data cleaning.  
14.[ADDRESS_9207] electronic data capture.  The eCRFs are supplied by [CONTACT_9928].  
eCRFs are to be completed on an ongoing basis during the study.  The medical chart and the 
source documents are the source of verification of data.  Paper CRFs and eCRFs should be 
completed according to the CRF instruction manual and relevant instructions in the study 
operations manual.  The investigator is responsible for maintaining accurate, complete and up-
to-date records, and for ensuring the completion of the eCRFs for each research participant.  
14.5 Data Acquisition and Entry  
Completed forms and electronic data will be entered into the AdvantageEDC system in accordance with the AdvantageEDC User‚Äôs Guide.  Only authorized individuals shall have 
access to eCR Fs. 
14.6 Data Editing  
Completed data is to be entered into AdvantageEDC.  If incomplete or inaccurate data are 
found, a query will be generated to the sites for a response.  Sites are to resolve data 
inconsistencies and errors and enter all corrections and changes into AdvantageEDC.  
55 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9208] final data quality assurance checks and ‚Äúlock‚Äù the study database from 
further modification.  The final analysis dataset will be returned to NIDA, as requested, for 
storage and archive.  
14.[ADDRESS_9209] data monitoring plan.  
An acceptable quality level prior to study lock or closeout will be established as a part of the 
data management plan.  Data quality summaries will be made available during the course of the 
protocol.  
 
56 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
15.0 PUBLICATIONS AND OTHER RIGHTS   
Per NIH policy, the results of the proposed trial are to be made available to the research 
community and to the public at large. The planning, preparation, and submission of publications 
will follow the policies of the Publications Committee of the CTN.  
57 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
16.0 SIGNATURES  
SPONSOR‚ÄôS REPRESENTATIVE (CCTN DESIGNEE)  
     
          
Printed Name   [CONTACT_9944] [CONTACT_9929]:  
 
‚Ä¢ I am in receipt of version 6.[ADDRESS_9210] this clinical study in 
accordance with the design and provisions specified therein.  
‚Ä¢ I agree to follow the protocol as written except in cases where necessary to protect the 
safety, rights, or welfare of a participant, an alteration is required, and the sponsor and IRB 
have been notified prior to the action.  
‚Ä¢ I will ensure that the requirements relating to obtaining informed consent and institutional review board (IRB) review and approval in 45 CFR 46 are met.  
‚Ä¢ I agree to personally conduct or supervise this investigation at this site and to ensure that 
all site staff assisting in the conduct of this study are adequately and appropriately trained 
to implement this version of the protocol and that they are qualified to meet the 
responsibilities to which they have been assigned.  
‚Ä¢ I agree to comply with all the applicable federal, state, and local regulations regarding the obligations of clinical investigators as required by [CONTACT_9930] (DHHS), th e state, and the IRB.  
 
SITE‚ÄôS PRINCIPAL INVESTIGATOR  
          
[INVESTIGATOR_9819]          
 
  
58 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
17.0 REFERENCES  
 
1. Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the treatment of addiction: 
methadone. J Addict Dis. Apr 2010;29(2):200- 216. 
2. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or 
methadone maintenance for opi[INVESTIGATOR_2561]. Cochrane Database Syst Rev. 
2008(2):CD002207. 
3. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opi[INVESTIGATOR_9820]. Cochrane Database Syst Rev. 2005(1):CD004330.  
4. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opi[INVESTIGATOR_9821]. Cochrane Database Syst Rev. 
2009(3):CD002209. 
5. Mark TL, Kassed CA, Vandivort -Warren R, Levit KR, Kranzler HR. Alcohol and opi[INVESTIGATOR_9822]: prescription trends, overall and by [CONTACT_9931]. Drug Alcohol Depend. Jan 1 2009;99(1 -3):345- 349. 
6. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance t reatment for opi[INVESTIGATOR_2561]. Cochrane Database Syst Rev. 
2011(4):CD001333. 
7. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained- release naltrexone for the 
treatment of opi[INVESTIGATOR_2561]: a randomized, placebo- controlled trial. Arch Gen 
Psychiatry. Feb 2006;63(2):[ADDRESS_9211], Silverman BL. Injectable 
extended- release naltrexone for opi[INVESTIGATOR_2561]: a double- blind, placebo- controlled, 
multicentre randomised trial. Lancet. Apr 30 2011;377(9776): [ADDRESS_9212], Wodak A. Authors' Reply. The Lancet. 2011;378(666).  
10. Wolfe D, Carrieri MP, Dasgupta N, Wodak A, Newman R, Bruce RD. Concerns about injectable naltrexone for opi[INVESTIGATOR_2561]. Lancet. Apr 30 2011;377(9776):1468 -1470.  
11. Volpi[INVESTIGATOR_9823], Rhines KC, Rhines JS, Volpi[INVESTIGATOR_9824], Alterman AI, O'Brien CP. Naltrexone and 
alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. Aug 1997;54(8):737 -
742. 
12. O'Brien CP. Naltrexone for alcohol dependence: compliance is a key issue. Addiction. Dec 
2001;96(12):1857.  
13. Rothenberg JL, Sullivan MA, Church SH, et al. Behavioral naltrexone therapy: an integrated 
treatment for opi[INVESTIGATOR_9825]. J Subst Abuse Treat. Dec 2002;23(4):351- 360. 
14. NIDA. Narcotic Antagonists: The Search for Long- acting Preparations. NIDA Research 
Monograph. 1976;R. Willette, ed. Rockville, MD.  
15. Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained- release naltrexone for opi[INVESTIGATOR_2560]. Cochrane Database Syst Rev. 2008(2):CD006140.  
16. Bigelow G, Preston K, Schmittner J, O'Brien C, Dong Q, Gastfriend D. A randomized, single-
dose, opi[INVESTIGATOR_9826] -release naltrexone in opi[INVESTIGATOR_2480]- using adults. 
Neuropsychopharmacology. 2006;31:S199.  
17. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot 
naltrexone: long -lasting antagonism of the effects of heroin in humans. 
Psychopharmacology (Berl). Feb 2002;159(4):351- 360. 
59 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
18. Chiang CN, Hawks R. Development of a buprenorphine- naloxone combination drug for the 
treatment of drug addiction. In: Harris LS, ed. Problems of Drug Dependence 1993: 
Proceedings of the 55th Annual Scientific Meeting, The College on Problems of Drug 
Dependence. Rockville, MD: US Department of Health and Human Services; 1994:p. 458.  
19. Chiang C, Bridge P, Creedon K, et al. Buprenorphine- naloxone combination product for 
treating opi[INVESTIGATOR_9827] (abstract). Paper presented at: Fifty -eighth Annual Scientific 
Meeting of the College on Problems of Drug Dependence; June, 1996; San Juan, Puerto 
Rico.  
20. Chiang CN, Bridge P, Hawks RL,  et al. The development of buprenorphine- naloxone 
products for treating opi[INVESTIGATOR_9825]. In: Harris LS, ed. Problems of Drug Dependence 
1995: Proceedings of the 57th Annual Scientific Meeting, The College on Problems of Drug 
Dependence. Vol NIDA Research Monograph Series, no. 162. Rockville, MD: US 
Department of Health and Human Services; 1996:p. 117. 
21. Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine- stabilized opi[INVESTIGATOR_9828]. Drug Alcohol Depend. Mar 1 1998;50(1):1 -8. 
22. Ciraulo DA, Hitzemann RJ, Somoza E, et al. Pharmacokinetics and pharmacodynamics of 
multiple sublingual buprenorphine tablets in dose- escalation trials. J Clin Pharmacol. Feb 
2006;46(2):179 -192. 
23. Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System -
Buprenorphine (PCSS -B): a novel project to expand/improve buprenorphine treatment. J 
Gen Intern Med. Sep 2010;25(9):[ADDRESS_9213]. Aug 2004;2(2):24- 29. 
25. Raisch DW, Fudala PJ, Saxon AJ, et al. Pharmacists' and technicians' perceptions and 
attitudes toward dispensing buprenorphine/ naloxone to patients with opi[INVESTIGATOR_2561]. J 
Am Pharm Assoc (2003). Jan -Feb 2005;45(1):23 -32. 
26. Fudala PJ, Bridge TP, Herbert S, et al. Office- based treatment of opi[INVESTIGATOR_9829] a 
sublingual -tablet formulation of buprenorphine and naloxone. N Engl J Med. Sep 4 
2003;349(10):949 -958. 
27. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opi[INVESTIGATOR_9825]: a multicenter, randomized clinical trial. Addiction. Apr 1998;93(4):475- 486. 
28. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate- day dosing regimens with 
the combination buprenorphine- nalox one tablet. Drug Alcohol Depend. Feb 1 2000;58(1 -
2):143 -152. 
29. Fiellin DA, Rosenheck RA, Kosten TR. Office -based treatment for opi[INVESTIGATOR_2561]: 
reaching new patient populations. Am J Psychiatry. Aug 2001;158(8):1200- 1204.  
30. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opi[INVESTIGATOR_2561]. Arch Gen Psychiatry. May 
1996;53(5):[ADDRESS_9214]. Clinical efficacy of buprenorphine: comparisons to methadone and 
placebo. Drug Alcohol Depend. May 21 2003;70([ADDRESS_9215]):S49- 57. 
32. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short -term buprenorphine-
naloxone for treatment of opi[INVESTIGATOR_2480]- addicted youth: a randomized trial. JAMA. Nov 5 
2008;300(17):[ADDRESS_9216], Johnson RE. A clinical trial of 
buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin 
Pharmacol Ther. Jan 1988;43(1):72 -78. 
60 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
34. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatm ent for opi[INVESTIGATOR_2560]. JAMA. May 27 1992;267(20):2750 -2755.  
35. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and 
methadone in the treatment of opi[INVESTIGATOR_2561]. Am J Psychiatry. Jul 1994;151(7):[ADDRESS_9217] Res. 1998;[ADDRESS_9218] 1:13- 18. 
37. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opi[INVESTIGATOR_2561]: self -reports, urinalysis, and addiction severity index. J Clin 
Psychopharmacol. Feb 1996;16(1):58 -67. 
38. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. May 1994;55(5):569 -580. 
39. Kuhlman JJ, Jr., Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma 
buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, 
maintenance and withdrawal from sublingual buprenorphine. Addiction. Apr 1998;93(4):[ADDRESS_9219], Badger GJ. Alternate -day dosing during buprenorphine 
treatment of opi[INVESTIGATOR_2561]. Life Sci. 1994;54(17):1215- 1228.  
41. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opi[INVESTIGATOR_9827]. II. Physiologic and behavioral effects of daily and alternate- day administration and 
abrupt withdrawal. Clin Pharmacol Ther. Apr 1990;47(4):525 -534. 
42. Huestis MA, Umbricht A, Preston KL, Cone EJ. Safety of burprenorphine: no clinically 
relevant cardio- resperatory depression at high IV doses. In: Harris LS, ed. Problems of Drug 
Dependence 1998: Proceedings of the 60th Annual Meeting, The College on Problems of Drug Dependence. Vol NIDA Research Monograph Series, no. 179. Rockville, MD: US 
Department of Health and Human Services; 1999:p. 62.  
43. Lange WR, Fudala PJ, Dax EM, Johnson RE. Safety and side- effects of buprenorphine in 
the clinical management of heroin addiction. Drug Alcohol Depend. Aug 1990;26(1):[ADDRESS_9220], Johnson RE. Buprenorphine: 
dose- related blockade of opi[INVESTIGATOR_9830]. J Pharmacol 
Exp Ther. Oct 1988;247(1):47 -53. 
45. Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in 
humans: partial agonist and blockade effects. J Pharmacol Exp Ther. Jul 1995;274(1):361-372. 
46. Singh RA, Mattoo SK, Malhotra A, Varma VK. Cases of buprenorphine abuse in India. Acta Psychiatr Scand. Jul  1992;86(1):46 -48. 
47. de Jong W, Tsegarelli T, Schouten E. Rapid assessment of injection drug use and HIV in the Republic of Georgia. J Drug Issues. 1999;29:843- 860. 
48. Ahmadi J, Maany I, Ahmadi M. Treatment of intravenous buprenorphine dependence: A 
randomized open clinical trial. German Journal of Psychiatry. 2003;6:23 -29. 
49. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction. Feb 2005;100(2):197 -205. 
50. Comer SD, Collins ED, Fischman MW. Intravenous buprenorphine self -administration by 
[CONTACT_9932]. J Pharmacol Exp Ther. Apr 2002;301(1):266 -276. 
51. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine- naloxone tablets 
in untreated IV drug users. Drug Alcohol Depend. Apr 17 2007;88(1):75- 78. 
61 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9221] 1983;38(10):[ADDRESS_9222] D, Courty P. Six deaths linked to concomitant use of 
buprenorphine and benzodiazepi[INVESTIGATOR_1651]. Addiction. Sep 1998;93(9):1385- 1392.  
54. Bridge TP, Fudala PJ, Herbert S, Leiderman DB. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office- based treatment for opi[INVESTIGATOR_9831]. Drug Alcohol Depend. May 21 2003;70([ADDRESS_9223]):S79- 85. 
55. Iribarne C, Pi[INVESTIGATOR_9832] D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60(22):1953 -
1964.  
56. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N -
dealkylations by [CONTACT_9933] -1 protease inhibitors. Drug Metab Dispos. Mar 1998;26(3):[ADDRESS_9224] SE, et al. A multi -site, two -phase, Prescription Opi[INVESTIGATOR_9833] (POATS): rationale, design, and methodology. Contemp Clin Trials. Mar 2010;31(2):189- 199. 
58. Ling W, Jacobs P, Hillhouse M, et al. From research to the real world: buprenorphine in the 
decade of the Clinical Trials Network. J Subst Abuse Treat. Jun 2010;[ADDRESS_9225] 1:S53- 60. 
59. Ling W, Amass L, Shoptaw S, et al. A multi -center randomized trial of buprenorphine-
naloxone versus clonidine for opi[INVESTIGATOR_9734]: findings from the National Institute on 
Drug Abuse Clinical Trials Network. Addiction. Aug 2005;100(8):1090- 1100.  
60. Sullivan MA, Rothenberg JL, Vosburg SK, et al. Predictors of retention in naltrexone maintenance for opi[INVESTIGATOR_2561]: analysis of a stage I trial. Am J Addict. Mar -Apr 
2006;15(2):150 -159. 
61. Carpenter KM, Jiang H, Sullivan MA, et al. Betting on change: modeling transitional 
probabilities to guide therapy development for opi[INVESTIGATOR_2561]. Psychol Addict Behav. 
Mar 2009;23(1):47- 55. 
62. Brooks AC, Comer SD, Sullivan MA, et al. Long -acting injectable versus oral naltrexone 
maintenance therapy with psychosocial intervention for heroin dependence: a quasi -
experiment. J Clin Psychiatry. Oct 2010;71(10):1371- 1378.  
63. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapi[INVESTIGATOR_9834]: the COMBINE study: a randomized controlled trial. 
JAMA. May 3 2006;295(17):2003 -2017.  
64. Trivedi MH, Wisniewski SR, Morris DW, et al.  Concise Health Risk Tracking scale: a brief 
self-report and clinician rating of suicidal risk. J Clin Psychiatry. Jun 2011;72(6):757- 64. 
65. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C -CASA): classification of suicidal events in the FDA's pediatric 
suicidal risk analysis of antidepressants. Am J Psychiatry . Jul 2007;164(7):1035- 1043.  
66. Sobell JL, Sobell MB. Timeline Follow -Back: A technique for assessing self -reported alcohol 
consumption. In: Litten R, Allen J, eds. Measuring Alcohol Consumption: The Human Press, 
Inc.; 1992.  
67. Fals-Stewart W, O'Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback 
reports of psychoactive substance use by [CONTACT_9934]- abusing patients: psychometric properties. J 
Consult Clin Psychol. Feb 2000;68(1):134- 144. 
68. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index . 
J Subst Abuse Treat. 1992;9(3):199 -213. 
62 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
69. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom 
Tolerance Questionnaire. J Behav Med. Apr 1989;12(2):[ADDRESS_9226] for 
Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. Sep 1991;86(9):1119- 1127.  
71. Navaline HA, Snider EC, Petro CJ, et al. Preparations for AIDS vaccine trials. An automated 
version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. AIDS Res Hum Retroviruses. 1994;[ADDRESS_9227] 2:S281- 283. 
72. Wallihan DB, Stump TE, Callahan CM. Accuracy of self -reported health services use and 
patterns of care among urban older adults. Med Care. Jul 1999; 37(7):662 -670. 
73. Harlow SD, Linet MS. Agreement between questionnaire data and medical records. The evidence for accuracy of recall. Am J Epi[INVESTIGATOR_5541]. Feb 1989;129(2):233- 248. 
74. Roberts RO, Bergstralh EJ, Schmidt L, Jacobsen SJ. Comparison of self -reported and 
medical record health care utilization measures. J Clin Epi[INVESTIGATOR_5541]. Sep 1996;49(9):989 -995. 
75. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient 
subsets. Biometrics. Jun 1985;41(2):361 -372. 
76. Klein DF, Ross DC. Reanalysis of the National Institute of Mental Health Treatment of 
Depression Collaborative Research Program General Effectiveness Report. 
Neuropsychopharmacology. May 1993;8(3):241- 251. 
77. Nunes E, Hu M, Pavlicova M, Campbell A, Miele G, Hien D, Klein DF. Baseline matters: The 
importance of covariation for baseline severity in the analysis of clinical trials. Am J Drug 
Alcohol Abuse. Sep 2011;37(5):446 -452. 
78. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment 
and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. Oct 15 2002;21(19):2917 -2930.  
79. Sullivan MA, Garawi F, Bisaga A, et al. Management of relapse in naltrexone maintenance 
for heroin dependence. Drug Alcohol Depend. Dec 1 2007;91(2 -3):289- 292. 
80. JAMA. CONSORT Statement.  http://jama.ama -assn.org/ . 
 
63 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
18.0 APPENDICES  
APPENDIX A ‚Äì Adverse Event Reporting Definitions and Procedures   
APPENDIX B ‚Äì Data Safety and Monitoring Plan  
APPENDIX C ‚Äì XR-NTX 
APPENDIX D ‚Äì BUP-NX 
64 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
APPENDIX A ‚Äì Adverse Event Reporting Definitions and Procedures  
Each participating site‚Äôs principal investigator [INVESTIGATOR_9835], including 
ensuring human research subject protection by [CONTACT_9935], report and monitor adverse events.  
 
Definition of Adverse Events and Serious Adverse Events 
An adverse event  (AE) is any untoward medical occurrence in humans, whether or not 
considered study drug/intervention related which occurs during the conduct of a clinical trial . 
Any change from baseline in clinical status or any findings from ECGs, lab results, x -rays, 
physical examinations, etc., that are considered clinically significant by [CONTACT_9936].  
Suspected adverse reaction is any adverse event for which there is a reasonable possibility 
that the study drug/intervention caused the adverse event. A reasonable possibility implies that there is evidence that the study drug/intervention caused the event.  
Adverse reaction  is any adverse event caused by [CONTACT_5257]/intervention.  
An adverse event, suspected adverse reaction, or adverse reaction is considered ‚Äú serious ‚Äù 
(i.e., a serious adverse event, serious suspected adverse reaction or serious adverse reaction) 
if, in the view of either the study clinician or sponsor, it:  
1. Results in death: A death occurring during the study or which comes to the attention of the study staff during the protocol -defined follow- up period, whether or not considered 
caused by [CONTACT_5257]/intervention, must be reported.  
2. Is life -threatening: Life- threatening means that the study participant was, in the opi[INVESTIGATOR_9836], at immediate risk of death from the reaction as it occurred and required immediate intervention.  
3. Requires inpatient hospi[INVESTIGATOR_1081].  
4. Results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.  
5. Is a congenital abnormality or birth defect.  
6. Important medical event that may not result in one of the above outcomes, but may jeopardize the health of the study participant or require medical or surgical intervention 
to prevent one of the outcomes listed in the above definition of serious event.   
Definition of Expectedness 
Any adverse event is considered ‚Äúunexpected‚Äù if it is not listed in the investigator brochure or 
the package insert or is not listed at the specificity or severity that has been observed. If neither is available then the protocol and informed consent form are used to determine an unexpected 
adverse event.  
65 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9228] in 
the assessment of worsening in intensity or severity of these conditions that would indicate an AE. Stable chronic conditions, such as arthritis, which are present prior to clinical trial entry and 
do not worsen are not considered AEs.  
Site Staff‚Äôs Role in Eliciting and Reporting Adverse Events  
Appropriately qualified and trained study personnel will elicit participant reporting of AEs and 
SAEs at each study visit designated to collect AEs. Adverse events (medical and/or psychiatric) 
assessment and collection will begin w hen the participant signs  the informed consent form and 
follow -up will continue through [ADDRESS_9229] study visit. Study personnel will obtain as 
much information as possible about the reported AE/SAE to complete the AE/SAE forms and will consult as warranted.  
Standard reporting, within 7 calendar days of the site becoming aware of the event, is required 
for reportable AEs. Expedited reporting (within 24 hours of their occurrence and/or site staff's 
knowledge of the event) is required for reportable SAEs (including death and life- threatening 
events). Local sites are responsible for reporting SAEs to their IRB, per their IRB‚Äôs guidelines.  
Site staff is required to enter reportable AEs and SAEs in the AdvantageEDC system. The AE 
form is used to capture reportable AEs  (as defined in the protocol). Additional information may 
need to be gathered to evaluate serious adverse events and to complete the appropriate CRFs 
and the summary. This process may include obtaining hospi[INVESTIGATOR_9837], medical 
records, autopsy records or any other type records or information necessary to provide a 
complete and clear pi[INVESTIGATOR_9838]. If the SAE is not resolved or stable at the time of the initial report or if new information becomes 
available after the initial report, follow -up information must be submitted as soon as possible.  
Reportable adverse events will be followed until resolution, stabilization or study end. Any serious adverse reactions will be followed until resolution or stabilization even beyond the end of 
the study.  
For the purpose of this study, the following AE classification will not require reporting in the data 
system but will be captured in the source documentation as medically indicated:  
‚Ä¢ Grade 1 (mild) unrelated adverse events  
This would typi[INVESTIGATOR_9792], cold, etc ., that were 
considered not reasonably associated with the use of the study drug/intervention.  
Events related to the injection of the study medication will be recorded on the Injection Site Abnormality  (INA) form  and will not be duplicate- reported on an AE form. Events related to 
withdrawal symptoms will be captured on the SOWS and HAM -D and will not be duplicate-
reported on an AE form.  Withdrawal symptoms not captured by [CONTACT_9925] -D should be 
reported as an AE. Events captured on study specific forms (INA, SOWS, HAM -D) will not be 
recorded separately as an AE, unless they meet the SAE definition. Any of these events that 
66 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
meet the definition of an SAE will be reported on the AE/SAE form set . Any spontaneous 
reporting of withdrawal symptoms by [CONTACT_9926]: withdrawal symptoms reported at visits without scheduled specific structured 
questionnaires (SOWS, HAM -D); and withdrawal symptoms not listed in the specific structured 
questionnaires (SOWS, HAM -D) reported at any visit . 
Site Staff‚Äôs Role in Assessing Severity and Causality of Adverse Events 
Appropriately qualified and trained study personnel will conduct an initial assessment of 
seriousness, severity, and causality when eliciting participant reporting of adverse events.  A 
study clinician will be expected  to review all reportable AEs for seriousness, severity, and 
causality on at least a weekly basis.  
Guidelines for Assessing Severity  
The severity of an adverse event refers to the intensity of the event.  
Guidelines for Determining Causality  
The study clinician will use the following question when assessing causal  relationship of an 
adverse event with study drug/intervention where an affirmative answer designates the event as 
a suspected adverse reaction:  
Is there a reasonable possibility that the study drug/intervention caused the event?  
Site Staff‚Äôs Role in Monitoring Adverse Events  
Site designated quality assurance personnel will review study sites and respective study data on 
a regular basis and will promptly advise sites to report any previously unreported safety issues and ensure that the reportable safety -related events are being followed to resolution and 
reported appropriately. Staff education, re -training or appropriate corrective action plan will be 
implemented at the participating site when unreported or unidentified reportable AEs or serious 
events are discovered, to ensure future identification and timely reporting by [CONTACT_779].  
Sponsor‚Äôs Role in Safety Management Procedures of AEs/SAEs  
A NIDA  CCTN assigned Medical Monitor is responsible for reviewing all serious adverse event 
reports. All reported SAEs will generate an e- mail notification to the Medical Monitor, 
pharmaceutical distributor  (Reckitt Benckiser Pharmaceuticals) lead investigator, and 
designees. All SAEs will be reviewed by [CONTACT_9937], if needed, 
additional information will be requested. The medical monitor will also report events to the 
sponsor , pharmaceutical distributor (Reckitt Benckiser Pharmaceuticals) and the Data and 
Safety Monitoring Board (DSMB). The DSMB will receive summary reports of all adverse events 
annually, at a minimum. The DSMB or the NIDA CCTN assigned Medical Monitor may also Grade 1  Mild Transient or mild discomfort (< 48 hours), no or minimal 
medical intervention/therapy required, hospi[INVESTIGATOR_9839] (non -prescription or single- use prescription therapy 
may be employed to relieve symptoms, e.g., aspi[INVESTIGATOR_9840], acetaminophen for post -surgical pain)  
Grade 2  Moderate  Mild to moderate limitation in activity some assistance may be 
needed; no or minimal intervention/therapy required, 
hospi[INVESTIGATOR_9841].  
Grade 3  Severe  Marked limitation in activity, some assistance usually required; 
medical intervention/ therapy required hospi[INVESTIGATOR_9841].  
67 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9230] apply his/her clinical judgment to determine whether or not an adverse 
event is of sufficient severity to require that the participant be withdrawn from further study 
medication administration. The study clinician should consult with the site principal investigator, 
the lead investigator and/or Medical Monitor as needed. If necessary, a study  clinician may 
suspend any trial treatments and institute the necessary medical therapy to protect a participant from any immediate danger. A participant may also voluntarily withdraw from treatment due to what he/she perceives as an intolerable adverse event or for any other reason. If voluntary 
withdrawal is requested, the participant will be asked to complete an end- of-medication visit to 
assure safety and to document end -of-medication outcomes and will be given recommendations 
for medical care and/or referrals to treatment, as necessary.  
  
68 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, [ADDRESS_9231] 
reporting  
Complete  
AE eCRF in EDC 
system  
within 7 days  Notify local IRB per 
IRB requirements  
Complete AE and SAE  
eCRF in EDC system  
within 7 days.  
 Study clinician reviews 
all relevant records and 
completes SAE report 
and documentation.  Reportable 
SAE 
AE reviewed by 
[CONTACT_9938] -up and 
reporting until event is 
resolved or stabilized  Expedited initial reporting 
within 24 hours via AE/SAE 
eCRFs in EDC  
EDC system will 
automatically notify 
Medical/Safety Monitor, 
Lead Investigator, and 
designees.  
 Reportable 
AE 
NO YES YES Record per site 
requirements 
report per IRB 
requirements  NO Serious?  
Record per site 
requirements 
report per IRB 
requirements  YES 
69 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
APPENDIX B ‚Äì Data Safety and Monitoring Plan 
1.0 BRIEF STUDY OVERVIEW  
The primary goal of the CTN -0051 study is to estimate the difference, if one exists, between XR -
NTX and BUP -NX in the distribution of the time to loss of persistent abstinence during the 6-
month trial.  As part of secondary outcomes, the study will evaluate and compare XR -NTX 
versus BUP -NX in regards to safety events, opi[INVESTIGATOR_2561], relapse, and r etention.  The 
misuse of alcohol, tobacco, and other drugs of abuse will be compared, in addition to the 
craving for opi[INVESTIGATOR_2437].  Depression, anxiety, and sub- acute withdrawal symptoms 
will also be compared between the two treatments.  Details for the definitions and reporting  of 
safety events are found in the protocol (Appendix A). 
2.0 OVERSIGHT OF CLINICAL RESPONSIBILITIES  
A. Site Principal Investigator  
[INVESTIGATOR_9842]‚Äôs Principal  Investigator ( PI) is responsible for study oversight, including 
ensuring human research subject protection by [CONTACT_9939], trained 
research staff and medical clinicians to assess, report, and monitor adverse events.  
Regarding safety and in accordance with FDA reporting requirements, all Adverse Events (AEs) occurring during the course of the clinical trial will be collected, documented, and reported by 
[CONTACT_9940] -investigators according to the Protocol. The assessment of Adverse 
Events (medical and/or psychiatric) will commence at the time of participant consent and will 
continue through [ADDRESS_9232] active treatment visit.  
The occurrence of AEs and Serious Adverse Events (SAEs) will be assessed at each clinic visit 
during the study.  Serious adverse events will be followed until resolved or considered stable, 
with reporting to the CCC Safety Monitor/Medical Monitor through the follow -up period.  
Standard reporting, within 7 days of the site becoming aware of the event, is required for 
reportable AEs. Expedited reporting (within 24 hours of their occurrence and/or site's knowledge of the event) is required for reportable SAEs (including death and life- threatening events).  
B. Medical Monitor/Safety Monitor  
The NIDA  CCTN  Clinical Coordin ating Center (CCC) Safety Monitor/Medical Monitor is 
responsible for reviewing all adverse events and serious adverse events reported. All SAEs will be reviewed at the time they are reported in the EDC.  The Medical Monitor will also indicate 
concurrence or not with the details of the report provided by [CONTACT_7880]. Where further 
information is needed the Safety monitor/Medical monitor will discuss the event with the site.  
Reviews of SAEs will be conducted in AdvantageEDC data system and will be a part of the 
safety database.  All AEs are reviewed on a weekly basis to observe trends or unusual events.  
Reports will be generated and presented for Data Safety Monitoring Board (DSMB) meetings.  
The DSMB will receive listing s of AEs and summary reports of all SAEs at a frequency 
requested by [CONTACT_4318], but at least annually.  Furthermore, the DSMB will be informed of expedited reports of SAEs   
C. Data And Safety Monitoring Board (DSMB)  
The NIDA CTN DSMB affiliated with this trial will be responsible for conducting per iodic reviews 
of accumulating safety, trial performance, and outcome data.  The DSMB will make recommendations to NIDA CCTN as to whether there is sufficient support for continuation of the 
trial, evidence that study procedures should be changed, or evidence that the trial (or a specific 
70 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
site) should be halted for reasons relating to safety of the study participants or inadequate trial 
performance (e.g., poor recruitment).  
Following each DSMB meeting, the NIDA CCTN will communicate the outcomes of the meeti ng, 
based on DSMB recommendations, in writing to the study Lead Investigator.  This communication detailing study safety information will be submitted to participating IRBs.  
D. Quality Assurance (QA) Monitoring  
The monitoring of the study site will be conducted on a regular basis using a combination of NIDA  CCTN CCC contract monitors and the RRTC site managers.  Investigators will host 
periodic visits for the NIDA CCTN CCC contract monitors and RRTC site managers.  The 
purpose of these visits is to assess compliance with GCP requirements and to document the integrity of the trial progress.  Areas of particular concern will be the review of 
Inclusion/Exclusion criteria, participant Informed Consent Forms, protocol adherence, safety 
monitoring, IRB reviews and approvals, regulatory documents, participant records, study drug accountability, and Principal Investigator [INVESTIGATOR_9815]. The monitors 
will interact with the site  staff  to identify issues and re- train the site as needed to enhance 
research quality.  
QA Site Visit Reports will be prepared by [CONTACT_9941].  These reports will be and forwarded to the site Principal Investigator, the study Lead Investigator and NIDA  CCTN . 
E. Management Of Risks To Participants  
Confidentiality  
Confidentiality of participant records will be secured by [CONTACT_9942], secure storage of any documents that have participant identifiers, and 
secure computing procedures for entering and transferring electronic data.  No identifying information will be disclosed in reports, publications or presentations.  
Information Meeting Reporting Requirements  
The consent form will specifically state the types of information that are required to be reported 
and the fact that the information will be reported as required.  These include suspected or known sexual or physical abuse of a child or elders, or threatened violence to self and/or others.  
Subject Protection  
The study clinician will evaluate all pertinent screening and baseline assessments prior to 
participant randomization to ensure that the participant is eligible and safe to enter the study. 
Adverse events (AEs) will be assessed and documented at each clinic visit.   Concomitant 
medications will be assessed at each medical management visit.   Individuals who experience an 
AE that compromises safe participation will be discontinued from further medication 
administration and provided referrals for other treatment or to specialized care.   Study personnel 
will request that the participant complete an end- of medication visit to assure safety and to 
document end- of-medication outcomes.  
Pregnancy  
Pregnancy is an exclusion criterion for study participation.  A positive pregnancy test post -
randomization will result in the cessation of study medication.  Participants who discontinue medications will be expected to continue with study visits.  Pregnancy test results will be 
recorded on the Pregnancy and Birth Control Assessment  CRF (PBC). R elated outcome 
information  will be recorded on the Pregnancy Outcome CRF (PO1, PO2, etc.) .  The site staff 
will follow the participant until an outcome of the pregnancy is known.  
 
71 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
Study Specific Risks  
Vivitrol¬Æ and Suboxone¬Æ block the effects of exogenous opi[INVESTIGATOR_9843].  After 
treatment, participant s are likely to have reduced tolerance to opi[INVESTIGATOR_2438].  Following Vivitrol¬Æ 
treatment, opi[INVESTIGATOR_9844] a dosing interval or after missing a dose could result in 
potentially life -threateni ng opi[INVESTIGATOR_9845] (involving respi[INVESTIGATOR_9846], 
circulatory collapse, etc.).  Attempting to overcome the blockade effects of Vivitrol¬Æ by 
[CONTACT_9943][INVESTIGATOR_9847].  Participants in this study will receive an information card that will notify clinicians that they are 
receiving Vivitrol
¬Æ or Suboxone¬Æ as part of a research study.  
3.0 DATA MANAGEMENT PROCEDURES  
This protocol will utilize a centralized Data and Statistics Center (DSC).  A web-based 
distributed data entry model will be implemented.  This electronic data capture system (AdvantageEDC) will be developed to ensure that guidelines and regulations surrounding the 
use of computerized systems in clinical trials are upheld.  
4.0 DATA AND STATISTICS CENTER RESPONSIBILITIES 
The DSC will: 1) develop and apply data management procedures to ensure the collection of 
accurate and good -quality data, 2) provide source documents and electronic Case Report 
Forms (eCRFs) for the collection of all data required by [CONTACT_1758], 3) develop data dictionaries 
for each eCRF that will comprehensively define each data element, 4) prepare instructions for the use of AdvantageEDC and for the completion of eCRFs, 5) conduct ongoing monitoring 
activities on study data collected from all participating sites, 6) perform data cleaning activities 
prior to any interim analyses and prior to the final study database lock.  
5.[ADDRESS_9233] -specific training and guidelines established by [CONTACT_9928].  
Data entry into the eCRFs shall be performed by [CONTACT_4539].  Selected eCRFs may 
also require the investigator‚Äôs electronic signature.  
The investigator at the site is responsible for maintaining accurate, complete and up- to-date 
research records.  In addition, the investigator is responsible for ensuring the timely completion 
of eCRFs for each research participant.  
6.[ADDRESS_9234] regular visits to sites, during which, audits comparing source documents to the data entered on the eCRF will be performed.  Any discrepancies 
identified between the source document and the eCRF will be corrected by [CONTACT_779].  
72 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
Trial progress and data status reports, which provide information on recruitment, availability of 
primary outcome, treatment exposure, attendance at long term follow -up visits, regulatory 
status, and data quality, will be generated daily and posted to a secure website.  These reports 
are available to the site, the corresponding RRTC , the lead investigator, the coordinating 
centers, and NIDA  CCTN, to monitor the sites‚Äô progress on the study.  
7.0 DATA LOCK AND TRANSFER  
At the conclusion of data collection for the study, the DSC will perform final data cleaning 
activities and will ‚Äúlock‚Äù the study database from further modification.  The final analysis dataset 
will be returned to NIDA  CCTN, as requested, for storage and archive.  
  
73 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
APPENDIX C ‚Äì XR-NTX 
74 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
75 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
76 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
77 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
78 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
79 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
80 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
81 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
82 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
83 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
84 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
85 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
86 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
87 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
88 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
89 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
90 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
91 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
92 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
93 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
94 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
95 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
96 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
97 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
98 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
99 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
100 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
101 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
102 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
103 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
104 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
  
105 
NIDA -CTN- 0051  Version 6.0  
Extended- Release Naltrexone vs. Buprenorphine for Opi[INVESTIGATOR_9720] (X:BOT)  August 31, 2015  
 
APPENDIX D ‚Äì BUP-NX 
 
 
  
106 
1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW

1,'$&71 9HUVLRQ
([WHQGHG5HOHDVH1DOWUH[RQHYV%XSUHQRUSKLQHIRU2SLRLG7UHDWP HQW;%27 $XJXVW
